1
|
Wagner B, Smieško M, Jakob RP, Mühlethaler T, Cramer J, Maier T, Rabbani S, Schwardt O, Ernst B. Analogues of the pan-selectin antagonist rivipansel (GMI-1070). Eur J Med Chem 2024; 272:116455. [PMID: 38728868 DOI: 10.1016/j.ejmech.2024.116455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2024] [Revised: 04/24/2024] [Accepted: 04/25/2024] [Indexed: 05/12/2024]
Abstract
The selectin family consisting of E-, P- and L-selectin plays dominant roles in atherosclerosis, ischemia-reperfusion injury, inflammatory diseases, and metastatic spreading of some cancers. An early goal in selectin-targeted drug discovery campaigns was to identify ligands binding to all three selectins, so-called pan-selectin antagonists. The physiological epitope, tetrasaccharide sialyl Lewisx (sLex, 1) binds to all selectins, albeit with very different affinities. Whereas P- and L-selectin require additional interactions contributed by sulfate groups for high binding affinity, E-selectin can functionally bind sLex-modified glycolipids and glycoproteins. Rivipansel (3) marked the first pan-selectin antagonist, which simultaneously interacted with both the sLex and the sulfate binding site. The aim of this contribution was to improve the pan-selectin affinity of rivipansel (3) by leveraging a new class of sLex mimetics in combination with an optimized linker length to the sulfate bearing group. As a result, the pan-selectin antagonist 11b exhibits an approximatively 5-fold improved affinity for E-, as well as P-selectin.
Collapse
Affiliation(s)
- Beatrice Wagner
- University of Basel, Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Martin Smieško
- University of Basel, Department of Pharmaceutical Sciences, Group Computational Pharmacy, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Roman P Jakob
- University of Basel, Department Biozentrum, Structural Area Focal Biology, Spitalstrasse 41, 4056, Basel, Switzerland
| | - Tobias Mühlethaler
- University of Basel, Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Jonathan Cramer
- Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany
| | - Tim Maier
- University of Basel, Department Biozentrum, Structural Area Focal Biology, Spitalstrasse 41, 4056, Basel, Switzerland
| | - Said Rabbani
- University of Basel, Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Oliver Schwardt
- University of Basel, Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Beat Ernst
- University of Basel, Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Klingelbergstrasse 50, 4056, Basel, Switzerland.
| |
Collapse
|
2
|
Cramer J, Jiang X, Aliu B, Ernst B. Combating DC-SIGN-mediated SARS-CoV-2 dissemination by glycan-mimicking polymers. Arch Pharm (Weinheim) 2024; 357:e2300396. [PMID: 38086006 DOI: 10.1002/ardp.202300396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 11/09/2023] [Accepted: 11/14/2023] [Indexed: 04/05/2024]
Abstract
Many viruses exploit the human C-type lectin receptor dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN) for cell entry and virus dissemination. An inhibition of DC-SIGN-mediated virus attachment by glycan-derived ligands has, thus, emerged as a promising strategy toward broad-spectrum antiviral therapeutics. In this contribution, several cognate fragments of oligomannose- and complex-type glycans grafted onto a poly-l-lysine scaffold are evaluated as polyvalent DC-SIGN ligands. The range of selected carbohydrate epitopes encompasses linear (α- d-Man-(1→2)-α- d-Man, α- d-Man-(1→2)-α- d-Man-(1→2)-α- d-Man-(1→3)-α- d-Man) and branched (α- d-Man-(1→6)-[α- d-Man-(1→3)]-α- d-Man) oligomannosides, as well as α- l-Fuc. The thermodynamics of binding are investigated on a mono- and multivalent level to shed light on the molecular details of the interactions with the tetravalent receptor. Cellular models of virus attachment and DC-SIGN-mediated virus dissemination reveal a high potency of the presented glycopolymers in the low pico- and nanomolar ranges, respectively. The high activity of oligomannose epitopes in combination with the biocompatible properties of the poly- l-lysine scaffold highlights the potential for further preclinical development of polyvalent DC-SIGN ligands.
Collapse
Affiliation(s)
- Jonathan Cramer
- Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Pharmazentrum, University of Basel, Basel, Switzerland
- Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Xiaohua Jiang
- Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Pharmazentrum, University of Basel, Basel, Switzerland
| | - Butrint Aliu
- Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Pharmazentrum, University of Basel, Basel, Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Pharmazentrum, University of Basel, Basel, Switzerland
| |
Collapse
|
3
|
Cramer J, Pero B, Jiang X, Bosko C, Silbermann M, Rabbani S, Wilke S, Nemli DD, Ernst B, Peczuh MW. Does size matter? - Comparing pyranoses with septanoses as ligands of the bacterial lectin FimH. Eur J Med Chem 2024; 268:116225. [PMID: 38367495 PMCID: PMC10964925 DOI: 10.1016/j.ejmech.2024.116225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Revised: 01/27/2024] [Accepted: 02/07/2024] [Indexed: 02/19/2024]
Abstract
The pharmacological modulation of disease-relevant carbohydrate-protein interactions represents an underexplored area of medicinal chemistry. One particular challenge in the design of glycomimetic compounds is the inherent instability of the glycosidic bond toward enzymatic cleavage. This problem has traditionally been approached by employing S-, N-, or C-glycosides with reduced susceptibility toward glycosidases. The application of ring-extended glycomimetics is an innovative approach to circumvent this issue. On the example of the bacterial adhesin FimH, it was explored how design principles from pyranose glycomimetics transfer to analogous septanose structures. A series of ring-extended FimH antagonists exhibiting the well-proven pharmacophore necessary for targeting the tyrosine-gate of FimH was synthesized. The resulting septanoses were evaluated for their affinity to the conformationally rigid isolated lectin domain of FimH (FimHLD), as well as a structurally flexible full-length FimH (FimHFL) construct. Some elements of potent mannoside-based FimH antagonists could be successfully transferred to septanose-based ligands, ultimately resulting in a 32-fold increase in binding affinity. Interestingly, the canonical ca. 100-fold loss of binding affinity between FimHLD and FimHFL is partly mitigated by the more flexible septanose antagonists, hinting at potentially differing interaction features of the flexible glycomimetics with intermediately populated states during the conformational transition of FimHFL.
Collapse
Affiliation(s)
- Jonathan Cramer
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland; Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany
| | - Bryant Pero
- Department of Chemistry, University of Connecticut, 55 North Eagleville Road, U3060, Storrs, CT, 06269, USA
| | - Xiaohua Jiang
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Cristin Bosko
- Department of Chemistry, University of Connecticut, 55 North Eagleville Road, U3060, Storrs, CT, 06269, USA
| | - Marleen Silbermann
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Said Rabbani
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Sebastian Wilke
- Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany
| | - Dilara D Nemli
- Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany
| | - Beat Ernst
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Mark W Peczuh
- Department of Chemistry, University of Connecticut, 55 North Eagleville Road, U3060, Storrs, CT, 06269, USA.
| |
Collapse
|
4
|
Conti G, Bärenwaldt A, Rabbani S, Mühlethaler T, Sarcevic M, Jiang X, Schwardt O, Ricklin D, Pieters RJ, Läubli H, Ernst B. Tetra- and Hexavalent Siglec-8 Ligands Modulate Immune Cell Activation. Angew Chem Int Ed Engl 2023; 62:e202314280. [PMID: 37947772 DOI: 10.1002/anie.202314280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 10/31/2023] [Accepted: 11/07/2023] [Indexed: 11/12/2023]
Abstract
Carbohydrate-binding proteins are generally characterized by poor affinities for their natural glycan ligands, predominantly due to the shallow and solvent-exposed binding sites. To overcome this drawback, nature has exploited multivalency to strengthen the binding by establishing multiple interactions simultaneously. The development of oligovalent structures frequently proved to be successful, not only for proteins with multiple binding sites, but also for proteins that possess a single recognition domain. Herein we present the syntheses of a number of oligovalent ligands for Siglec-8, a monomeric I-type lectin found on eosinophils and mast cells, alongside the thermodynamic characterization of their binding. While the enthalpic contribution of each binding epitope was within a narrow range to that of the monomeric ligand, the entropy penalty increased steadily with growing valency. Additionally, we observed a successful agonistic binding of the tetra- and hexavalent and, to an even larger extent, multivalent ligands to Siglec-8 on immune cells and modulation of immune cell activation. Thus, triggering a biological effect is not restricted to multivalent ligands but could be induced by low oligovalent ligands as well, whereas a monovalent ligand, despite binding with similar affinity, showed an antagonistic effect.
Collapse
Affiliation(s)
- Gabriele Conti
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
- Chemical Biology and Drug Discovery Group, Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands
| | - Anne Bärenwaldt
- Laboratory for Cancer Immunotherapy, Department of Biomedicine, University of Basel, Hebelstrasse 20, 4051, Basel, Switzerland
- Division of Medical Oncology, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland
| | - Said Rabbani
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Tobias Mühlethaler
- Biophysics Facility, Department Biozentrum, University of Basel, Spitalstrasse 41, 4056, Basel, Switzerland
| | - Mirza Sarcevic
- Laboratory for Cancer Immunotherapy, Department of Biomedicine, University of Basel, Hebelstrasse 20, 4051, Basel, Switzerland
- Division of Medical Oncology, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland
| | - Xiaohua Jiang
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Oliver Schwardt
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Daniel Ricklin
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Roland J Pieters
- Chemical Biology and Drug Discovery Group, Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands
| | - Heinz Läubli
- Laboratory for Cancer Immunotherapy, Department of Biomedicine, University of Basel, Hebelstrasse 20, 4051, Basel, Switzerland
- Division of Medical Oncology, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland
| | - Beat Ernst
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| |
Collapse
|
5
|
Arzt-Gradwohl L, Annik Herzog S, Aberer W, Alfaya Arias T, Antolín-Amérigo D, Bonadonna P, Boni E, Bożek A, Chełmińska M, Ernst B, Frelih N, Gawlik R, Gelincik A, Hawranek T, Hoetzenecker W, Jiménez Blanco A, Kita K, Kendirlinan R, Košnik M, Laipold K, Lang R, Marchi F, Mauro M, Nittner-Marszalska M, Poziomkowska-Gęsicka I, Pravettoni V, Preziosi D, Quercia O, Reider N, Rosiek-Biegus M, Ruiz-Leon B, Schrautzer C, Serrano P, Sin A, Ayşe Sin B, Stoevesandt J, Trautmann A, Vachová M, Johannes Sturm G. Influencing factors on the safety and effectiveness of venom immunotherapy. J Investig Allergol Clin Immunol 2023; 35:0. [PMID: 37937715 DOI: 10.18176/jiaci.0967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2023] Open
Abstract
BACKGROUND AND OBJECTIVE The safety profile of venom immunotherapy (VIT) is a relevant issue and considerable differences in safety and efficacy of VIT have been reported. The primary aim of this study was to evaluate the safety of ACE inhibitors and beta-blockers during VIT, which has already been published. For a second analysis, data concerning premedication and venom preparations in relation to systemic adverse events (AE) during the up-dosing phase and the first year of the maintenance phase were evaluated as well as the outcome of field stings and sting challenges. METHODS The study was conducted as an open, prospective, observational, multicenter study. In total, 1,425 patients were enrolled and VIT was performed in 1,342 patients. RESULTS Premedication with oral antihistamines was taken by 52.1% of patients during the up-dosing and 19.7% of patients during the maintenance phase. Taking antihistamines had no effect on the frequency of systemic AE (p=0.11) but large local reactions (LLR) were less frequently seen (OR: 0.74; 95% CI: 0.58-0.96; p=0.02). Aqueous preparations were preferentially used for up-dosing (73.0%) and depot preparations for the maintenance phase (64.5%). The type of venom preparation neither had an influence on the frequency of systemic AE nor on the effectiveness of VIT (p=0.26 and p=0.80, respectively), while LLR were less frequently seen when depot preparations were used (p<0.001). CONCLUSION Pretreatment with oral antihistamines during VIT significantly reduces the frequency of LLR but not systemic AE. All venom preparations used were equally effective and did not differ in the frequency of systemic AE.
Collapse
Affiliation(s)
- L Arzt-Gradwohl
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - S Annik Herzog
- Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, Graz, Austria
| | - W Aberer
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - T Alfaya Arias
- Allergy Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - D Antolín-Amérigo
- Servicio de Enfermedades del Sistema Inmune-Alergia, Hospital Universitario Príncipe de Asturias, Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Madrid, Spain
- Servicio de Alergia, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain
| | - P Bonadonna
- Allergy Unit, Verona General Hospital, Verona, Italy
| | - E Boni
- Laboratorio Unico Metropolitano, Maggiore Hospital, Bologna, Italy
| | - A Bożek
- Clinical Department of Internal Diseases, Dermatology, and Allergology, Medical University of Silesia, Zabrze, Poland
| | - M Chełmińska
- Allergology Department, Medical University of Gdańsk, Gdańsk, Poland
| | - B Ernst
- Department of Dermatology, General Hospital Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria
| | - N Frelih
- University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia
| | - R Gawlik
- Department of Internal Medicine, Allergy, and Clinical Immunology, Silesian University of Medicine, Katowice, Poland
| | - A Gelincik
- Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
| | - T Hawranek
- Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - W Hoetzenecker
- Department of Dermatology, Kepler University Hospital and Medical Faculty, Johannes Kepler University, Linz, Austria
| | - A Jiménez Blanco
- Allergy Unit, Hospital Central de la Cruz Roja. Faculty of Medicine, Alfonso X El Sabio University, ARADyAL, Madrid, Spain
| | - K Kita
- Allergology Department, Medical University of Gdańsk, Gdańsk, Poland
| | - R Kendirlinan
- Department of Pulmonary Diseases, Division of Immunology and Allergy, Faculty of Medicine, Ankara University, Ankara, Türkiye
| | - M Košnik
- University Clinic of Respiratory and Allergic Diseases, Golnik and Medical Faculty Ljubljana, Slovenia
| | - K Laipold
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - R Lang
- Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - F Marchi
- SD Allergologia Clinica, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - M Mauro
- Allergy Unit, Sant´Anna Hospital, Como, Italy
| | - M Nittner-Marszalska
- Department of Internal Diseases, Pulmonology and Allergology, Medical University of Wroclaw, Wroclaw, Poland
| | | | - V Pravettoni
- Department of Internal Medicine, Fondazione IRCCS Ca´ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - D Preziosi
- Allergy Unit, Sant´Anna Hospital, Como, Italy
| | - O Quercia
- High Specialization Unit of Allergology, Hospital of Faenza, AUSL (Local Health Unit) of Romagna, Romagna, Italy
| | - N Reider
- Department of Dermatology, Venereology, and Allergology, Medical University of Innsbruck, Innsbruck, Austria
| | - M Rosiek-Biegus
- Department of Internal Diseases, Pulmonology and Allergology, Medical University of Wroclaw, Wroclaw, Poland
| | - B Ruiz-Leon
- Allergy Section of University Hospital Reina Sofia, ARADyAL Network, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain
| | - C Schrautzer
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - P Serrano
- Allergy Section of University Hospital Reina Sofia, ARADyAL Network, Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain
| | - A Sin
- Department of Internal Medicine, Division of Allergy and Immunology, Medical Faculty, Ege University, Izmir, Türkiye
| | - B Ayşe Sin
- Department of Pulmonary Diseases, Division of Immunology and Allergy, Faculty of Medicine, Ankara University, Ankara, Türkiye
| | - J Stoevesandt
- Department of Dermatology and Allergy, University Hospital Würzburg, Würzburg, Germany
| | - A Trautmann
- Department of Dermatology and Allergy, University Hospital Würzburg, Würzburg, Germany
| | - M Vachová
- Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- Department of Immunology and Allergology, University Hospital Pilsen, Czech Republic
| | - G Johannes Sturm
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
- Allergy Outpatient Clinic Reumannplatz, Vienna, Austria
| |
Collapse
|
6
|
Scaglione F, Minghetti P, Ambrosio F, Ernst B, Ficarra V, Gobbi M, Naber K, Schellekens H. Nature of the Interaction of Alpha-D-Mannose and Escherichia coli Bacteria, and Implications for its Regulatory Classification. A Delphi Panel European Consensus Based on Chemistry and Legal Evidence. Ther Innov Regul Sci 2023; 57:1153-1166. [PMID: 37578736 PMCID: PMC10579141 DOI: 10.1007/s43441-023-00548-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 06/05/2023] [Indexed: 08/15/2023]
Abstract
The nature of alpha-D-mannose-natural aldohexose sugar, C-2 glucose epimer, whose intended use is for preventing urinary tract infections-in the interaction with E. coli is addressed in order to drive the issue of its regulatory classification as a medicinal product or medical device. PRISMA systematic review approach was applied; Delphi Panel method was used to target consensus on statements retrieved from evidence. Based on regulatory definitions and research evidence, the mechanism of D-mannose does not involve a metabolic or immunological action while there is uncertainty regarding the pharmacological action. Specific interaction between the product and the bacteria within the body occurs, but its nature is inert: it does not induce a direct response activating or inhibiting body processes. Moreover, the action of D-mannose takes place, even if inside the bladder, outside the epithelium on bacteria that have not yet invaded the urothelial tissue. Therefore, its mechanism of action is not directed to host structures but to structures (bacteria) external to the host's tissues. On the basis of current regulation, the uncertainty as regard a pharmacological action of alpha-D-mannose makes possible its medical device classification: new regulations and legal judgments can add further considerations. From a pharmacological perspective, research is driven versus synthetic mannosides: no further considerations are expected on alpha-D-mannose.
Collapse
Affiliation(s)
- Francesco Scaglione
- Clinical Pharmacology and Toxicology Unit -GOM Niguarda, GOM Niguarda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
| | - Paola Minghetti
- Department of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy
| | | | - Beat Ernst
- Group Molecular Pharmacy Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Vincenzo Ficarra
- Department of Human and Pediatric Pathology “Gaetano Barresi”, Urologic Section, University of Messina, Piazza Pugliatti, 1, Messina, Italy
| | - Marco Gobbi
- Laboratory of Pharmacodynamics and Pharmacokinetics, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156 Milan, MI Italy
| | - Kurt Naber
- Department of Urology, Technical University of Munich, Munich, Germany
- Department of Urology, Technical University of Munich, Karl-Bickleder Str. 44C, 94315 Straubing, Germany
| | - Huub Schellekens
- Faculty of Sciences, Utrecht University, PO Box 80125, 3508 TC Utrecht, The Netherlands
| |
Collapse
|
7
|
Bozzola T, Scalise M, Larsson CU, Newton-Vesty MC, Rovegno C, Mitra A, Cramer J, Wahlgren WY, Radhakrishnan Santhakumari P, Johnsson RE, Schwardt O, Ernst B, Friemann R, Dobson RCJ, Indiveri C, Schelin J, Nilsson UJ, Ellervik U. Sialic Acid Derivatives Inhibit SiaT Transporters and Delay Bacterial Growth. ACS Chem Biol 2022; 17:1890-1900. [PMID: 35675124 PMCID: PMC9295122 DOI: 10.1021/acschembio.2c00321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
![]()
Antibiotic resistance
is a major worldwide concern, and new drugs
with mechanistically novel modes of action are urgently needed. Here,
we report the structure-based drug design, synthesis, and evaluation
in vitro and in cellular systems of sialic acid derivatives able to
inhibit the bacterial sialic acid symporter SiaT. We designed and
synthesized 21 sialic acid derivatives and screened their affinity
for SiaT by a thermal shift assay and elucidated the inhibitory mechanism
through binding thermodynamics, computational methods, and inhibitory
kinetic studies. The most potent compounds, which have a 180-fold
higher affinity compared to the natural substrate, were tested in
bacterial growth assays and indicate bacterial growth delay in methicillin-resistant Staphylococcus aureus. This study represents the
first example and a promising lead in developing sialic acid uptake
inhibitors as novel antibacterial agents.
Collapse
Affiliation(s)
- Tiago Bozzola
- Centre for Analysis and Synthesis, Department of Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden.,Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Mariafrancesca Scalise
- Department DiBEST (Biologia, Ecologia, Scienze della Terra) Unit of Biochemistry and Molecular Biotechnology, University of Calabria, Via P. Bucci 4C, 87036 Arcavacata di Rende, Italy
| | - Christer U Larsson
- Division of Applied Microbiology, Department of Chemistry, Lund University, 22100 Lund, Sweden
| | - Michael C Newton-Vesty
- Biomolecular Interaction Centre and School of Biological Sciences, University of Canterbury, 8140 Christchurch, New Zealand
| | - Caterina Rovegno
- Centre for Analysis and Synthesis, Department of Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden
| | - Ankita Mitra
- Centre for Analysis and Synthesis, Department of Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden
| | - Jonathan Cramer
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.,Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University of Düsseldorf, Universitätsstraße 1, 40225 Düsseldorf, Germany
| | - Weixiao Yuan Wahlgren
- Department of Chemistry and Molecular Biology, University of Gothenburg, Box 462, S-40530 Gothenburg, Sweden
| | - Partha Radhakrishnan Santhakumari
- Institute for Stem Cell Science and Regenerative Medicine, Bengaluru, Karnataka 560065, India.,Manipal Academy of Higher Education, Tiger Circle Road, Manipal, Karnataka 576104, India
| | | | - Oliver Schwardt
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Beat Ernst
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Rosmarie Friemann
- Department of Clinical Microbiology, Sahlgrenska University Hospital, 41345 Gothenburg, Sweden.,Centre for Antibiotic Resistance Research (CARe), University of Gothenburg, 40530 Gothenburg, Sweden
| | - Renwick C J Dobson
- Biomolecular Interaction Centre and School of Biological Sciences, University of Canterbury, 8140 Christchurch, New Zealand.,Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Cesare Indiveri
- Department DiBEST (Biologia, Ecologia, Scienze della Terra) Unit of Biochemistry and Molecular Biotechnology, University of Calabria, Via P. Bucci 4C, 87036 Arcavacata di Rende, Italy.,Institute of Biomembranes, Bioenergetics and Molecular Biotechnology (IBIOM), National Research Council-CNR, Via Amendola 122/O, 70126 Bari, Italy
| | - Jenny Schelin
- Division of Applied Microbiology, Department of Chemistry, Lund University, 22100 Lund, Sweden
| | - Ulf J Nilsson
- Centre for Analysis and Synthesis, Department of Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden
| | - Ulf Ellervik
- Centre for Analysis and Synthesis, Department of Chemistry, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden
| |
Collapse
|
8
|
Dätwyler P, Jiang X, Wagner B, Varga N, Mühlethaler T, Hostettler K, Rabbani S, Schwardt O, Ernst B. Prodrugs of E-selectin Antagonists with Enhanced Pharmacokinetic Properties. ChemMedChem 2021; 17:e202100634. [PMID: 34870892 DOI: 10.1002/cmdc.202100634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Indexed: 11/10/2022]
Abstract
Because of their large polar surface area, carbohydrates often exhibit insufficient pharmacokinetic properties. Specifically, the carboxylic acid function of the tetrasaccharide sialyl Lewisx , a pharmacophore crucial for the formation of a salt bridge with selectins, prevents oral availability. A common approach is the transfer of carboxylic acid into ester prodrugs. Once the prodrug is either actively or passively absorbed, the active principle is released by hydrolysis. In the present study, ester prodrugs of selectin antagonists with aliphatic promoieties were synthesized and their potential for oral availability was investigated in vitro and in vivo. The addition of lipophilic ester moieties to overcome insufficient lipophilicity improved passive permeation into enterocytes, however at the same time supported efflux back to the small intestines as well as oxidation into non-hydrolysable metabolites. In summary, our examples demonstrate that different modifications of carbohydrates can result in opposing effects and have to be studied in their entirety.
Collapse
Affiliation(s)
- Philipp Dätwyler
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Xiaohua Jiang
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Beatrice Wagner
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Norbert Varga
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Tobias Mühlethaler
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Katja Hostettler
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Said Rabbani
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Oliver Schwardt
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| |
Collapse
|
9
|
Wawrzinek R, Wamhoff EC, Lefebre J, Rentzsch M, Bachem G, Domeniconi G, Schulze J, Fuchsberger FF, Zhang H, Modenutti C, Schnirch L, Marti MA, Schwardt O, Bräutigam M, Guberman M, Hauck D, Seeberger PH, Seitz O, Titz A, Ernst B, Rademacher C. A Remote Secondary Binding Pocket Promotes Heteromultivalent Targeting of DC-SIGN. J Am Chem Soc 2021; 143:18977-18988. [PMID: 34748320 PMCID: PMC8603350 DOI: 10.1021/jacs.1c07235] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
![]()
Dendritic cells (DC)
are antigen-presenting cells coordinating
the interplay of the innate and the adaptive immune response. The
endocytic C-type lectin receptors DC-SIGN and Langerin display expression
profiles restricted to distinct DC subtypes and have emerged as prime
targets for next-generation immunotherapies and anti-infectives. Using
heteromultivalent liposomes copresenting mannosides bearing aromatic
aglycones with natural glycan ligands, we serendipitously discovered
striking cooperativity effects for DC-SIGN+ but not for
Langerin+ cell lines. Mechanistic investigations combining
NMR spectroscopy with molecular docking and molecular dynamics simulations
led to the identification of a secondary binding pocket for the glycomimetics.
This pocket, located remotely of DC-SIGN’s carbohydrate bindings
site, can be leveraged by heteromultivalent avidity enhancement. We
further present preliminary evidence that the aglycone allosterically
activates glycan recognition and thereby contributes to DC-SIGN-specific
cell targeting. Our findings have important implications for both
translational and basic glycoscience, showcasing heteromultivalent
targeting of DCs to improve specificity and supporting potential allosteric
regulation of DC-SIGN and CLRs in general.
Collapse
Affiliation(s)
- Robert Wawrzinek
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany
| | - Eike-Christian Wamhoff
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany.,Department of Chemistry and Biochemistry, Freie University of Berlin, 14195 Berlin, Germany
| | - Jonathan Lefebre
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany.,Department of Chemistry and Biochemistry, Freie University of Berlin, 14195 Berlin, Germany
| | - Mareike Rentzsch
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany.,Department of Chemistry and Biochemistry, Freie University of Berlin, 14195 Berlin, Germany
| | - Gunnar Bachem
- Department of Chemistry, Humboldt University of Berlin, 12489 Berlin, Germany
| | - Gary Domeniconi
- Department of Chemistry, Humboldt University of Berlin, 12489 Berlin, Germany
| | - Jessica Schulze
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany.,Department of Chemistry and Biochemistry, Freie University of Berlin, 14195 Berlin, Germany
| | - Felix F Fuchsberger
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany.,Department of Chemistry and Biochemistry, Freie University of Berlin, 14195 Berlin, Germany
| | - Hengxi Zhang
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany.,Department of Chemistry and Biochemistry, Freie University of Berlin, 14195 Berlin, Germany
| | - Carlos Modenutti
- Departamento de Química Biológica e IQUIBICEN-CONICET, Universidad de Buenos Aires, C1428EHA Ciudad de Buenos Aires, Argentina
| | - Lennart Schnirch
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany.,Department of Chemistry and Biochemistry, Freie University of Berlin, 14195 Berlin, Germany
| | - Marcelo A Marti
- Departamento de Química Biológica e IQUIBICEN-CONICET, Universidad de Buenos Aires, C1428EHA Ciudad de Buenos Aires, Argentina
| | - Oliver Schwardt
- Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland
| | - Maria Bräutigam
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany
| | - Mónica Guberman
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany
| | - Dirk Hauck
- Chemical Biology of Carbohydrates, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, 66123 Saarbrücken, Germany.,German Centre for Infection Research, Campus Hannover-Braunschweig, 38124 Braunschweig, Germany
| | - Peter H Seeberger
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany.,Department of Chemistry and Biochemistry, Freie University of Berlin, 14195 Berlin, Germany
| | - Oliver Seitz
- Department of Chemistry, Humboldt University of Berlin, 12489 Berlin, Germany
| | - Alexander Titz
- Chemical Biology of Carbohydrates, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, 66123 Saarbrücken, Germany.,German Centre for Infection Research, Campus Hannover-Braunschweig, 38124 Braunschweig, Germany.,Department of Chemistry, Saarland University, 66123 Saarbrücken, Germany
| | - Beat Ernst
- Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland
| | - Christoph Rademacher
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany.,Department of Chemistry and Biochemistry, Freie University of Berlin, 14195 Berlin, Germany.,University of Vienna, Department of Pharmaceutical Sciences, Althanstrasse 14, 1090 Vienna, Austria.,University of Vienna, Department of Microbiology, Immunology and Genetics, Max F. Perutz Laboratories, Biocenter 5, 1030 Vienna, Austria
| |
Collapse
|
10
|
Cramer J, Lakkaichi A, Aliu B, Jakob RP, Klein S, Cattaneo I, Jiang X, Rabbani S, Schwardt O, Zimmer G, Ciancaglini M, Abreu Mota T, Maier T, Ernst B. Sweet Drugs for Bad Bugs: A Glycomimetic Strategy against the DC-SIGN-Mediated Dissemination of SARS-CoV-2. J Am Chem Soc 2021; 143:17465-17478. [PMID: 34652144 DOI: 10.1021/jacs.1c06778] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The C-type lectin receptor DC-SIGN is a pattern recognition receptor expressed on macrophages and dendritic cells. It has been identified as a promiscuous entry receptor for many pathogens, including epidemic and pandemic viruses such as SARS-CoV-2, Ebola virus, and HIV-1. In the context of the recent SARS-CoV-2 pandemic, DC-SIGN-mediated virus dissemination and stimulation of innate immune responses has been implicated as a potential factor in the development of severe COVID-19. Inhibition of virus binding to DC-SIGN, thus, represents an attractive host-directed strategy to attenuate overshooting innate immune responses and prevent the progression of the disease. In this study, we report on the discovery of a new class of potent glycomimetic DC-SIGN antagonists from a focused library of triazole-based mannose analogues. Structure-based optimization of an initial screening hit yielded a glycomimetic ligand with a more than 100-fold improved binding affinity compared to methyl α-d-mannopyranoside. Analysis of binding thermodynamics revealed an enthalpy-driven improvement of binding affinity that was enabled by hydrophobic interactions with a loop region adjacent to the binding site and displacement of a conserved water molecule. The identified ligand was employed for the synthesis of multivalent glycopolymers that were able to inhibit SARS-CoV-2 spike glycoprotein binding to DC-SIGN-expressing cells, as well as DC-SIGN-mediated trans-infection of ACE2+ cells by SARS-CoV-2 spike protein-expressing viruses, in nanomolar concentrations. The identified glycomimetic ligands reported here open promising perspectives for the development of highly potent and fully selective DC-SIGN-targeted therapeutics for a broad spectrum of viral infections.
Collapse
Affiliation(s)
- Jonathan Cramer
- University of Basel, Institute of Molecular Pharmacy, Pharmacenter of the University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.,Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University of Düsseldorf, Universitätsstraße 1, 40225 Düsseldorf, Germany
| | - Adem Lakkaichi
- University of Basel, Institute of Molecular Pharmacy, Pharmacenter of the University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Butrint Aliu
- University of Basel, Institute of Molecular Pharmacy, Pharmacenter of the University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Roman P Jakob
- Department Biozentrum, Focal Area Structural Biology, University of Basel, Klingelbergstrasse 70, 4056 Basel, Switzerland
| | - Sebastian Klein
- University of Basel, Institute of Molecular Pharmacy, Pharmacenter of the University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Ivan Cattaneo
- University of Basel, Institute of Molecular Pharmacy, Pharmacenter of the University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Xiaohua Jiang
- University of Basel, Institute of Molecular Pharmacy, Pharmacenter of the University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Said Rabbani
- University of Basel, Institute of Molecular Pharmacy, Pharmacenter of the University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Oliver Schwardt
- University of Basel, Institute of Molecular Pharmacy, Pharmacenter of the University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Gert Zimmer
- Institute of Virology and Immunology, Sensemattstrasse 293, 3147 Mittelhäusern, Switzerland
| | - Matias Ciancaglini
- Department Biomedicine, University of Basel, Petersplatz 8, 4051 Basel, Switzerland
| | - Tiago Abreu Mota
- Department Biomedicine, University of Basel, Petersplatz 8, 4051 Basel, Switzerland
| | - Timm Maier
- Department Biozentrum, Focal Area Structural Biology, University of Basel, Klingelbergstrasse 70, 4056 Basel, Switzerland
| | - Beat Ernst
- University of Basel, Institute of Molecular Pharmacy, Pharmacenter of the University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| |
Collapse
|
11
|
Cramer J, Aliu B, Jiang X, Sharpe T, Pang L, Hadorn A, Rabbani S, Ernst B. Poly-l-lysine Glycoconjugates Inhibit DC-SIGN-mediated Attachment of Pandemic Viruses. ChemMedChem 2021; 16:2345-2353. [PMID: 34061468 DOI: 10.1002/cmdc.202100348] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Indexed: 12/27/2022]
Abstract
The C-type lectin receptor DC-SIGN mediates interactions with envelope glycoproteins of many viruses such as SARS-CoV-2, ebola, and HIV and contributes to virus internalization and dissemination. In the context of the recent SARS-CoV-2 pandemic, involvement of DC-SIGN has been linked to severe cases of COVID-19. Inhibition of the interaction between DC-SIGN and viral glycoproteins has the potential to generate broad spectrum antiviral agents. Here, we demonstrate that mannose-functionalized poly-l-lysine glycoconjugates efficiently inhibit the attachment of viral glycoproteins to DC-SIGN-presenting cells with picomolar affinity. Treatment of these cells leads to prolonged receptor internalization and inhibition of virus binding for up to 6 h. Furthermore, the polymers are fully bio-compatible and readily cleared by target cells. The thermodynamic analysis of the multivalent interactions reveals enhanced enthalpy-driven affinities and promising perspectives for the future development of multivalent therapeutics.
Collapse
Affiliation(s)
- Jonathan Cramer
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.,Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University of Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany
| | - Butrint Aliu
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Xiaohua Jiang
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Timothy Sharpe
- Biophysics Facility, Biocenter of the University of Basel, Klingelbergstrasse 70, 4056, Basel, Switzerland
| | - Lijuan Pang
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Adrian Hadorn
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Said Rabbani
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| |
Collapse
|
12
|
Lal K, Bermeo R, Cramer J, Vasile F, Ernst B, Imberty A, Bernardi A, Varrot A, Belvisi L. Prediction and Validation of a Druggable Site on Virulence Factor of Drug Resistant Burkholderia cenocepacia*. Chemistry 2021; 27:10341-10348. [PMID: 33769626 PMCID: PMC8360069 DOI: 10.1002/chem.202100252] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Indexed: 12/12/2022]
Abstract
Burkholderia cenocepacia is an opportunistic Gram‐negative bacterium that causes infections in patients suffering from chronic granulomatous diseases and cystic fibrosis. It displays significant morbidity and mortality due to extreme resistance to almost all clinically useful antibiotics. The bacterial lectin BC2L‐C expressed in B. cenocepacia is an interesting drug target involved in bacterial adhesion and subsequent deadly infection to the host. We solved the first high resolution crystal structure of the apo form of the lectin N‐terminal domain (BC2L‐C‐nt) and compared it with the ones complexed with carbohydrate ligands. Virtual screening of a small fragment library identified potential hits predicted to bind in the vicinity of the fucose binding site. A series of biophysical techniques and X‐ray crystallographic screening were employed to validate the interaction of the hits with the protein domain. The X‐ray structure of BC2L‐C‐nt complexed with one of the identified active fragments confirmed the ability of the site computationally identified to host drug‐like fragments. The fragment affinity could be determined by titration microcalorimetry. These structure‐based strategies further provide an opportunity to elaborate the fragments into high affinity anti‐adhesive glycomimetics, as therapeutic agents against B. cenocepacia.
Collapse
Affiliation(s)
- Kanhaya Lal
- Universita' degli Studi di Milano, Dipartimento di Chimica, via Golgi 19, I-20133, Milano, Italy.,Université Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France
| | - Rafael Bermeo
- Universita' degli Studi di Milano, Dipartimento di Chimica, via Golgi 19, I-20133, Milano, Italy.,Université Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France
| | - Jonathan Cramer
- University of Basel, Department of Pharmaceutical Sciences, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Francesca Vasile
- Universita' degli Studi di Milano, Dipartimento di Chimica, via Golgi 19, I-20133, Milano, Italy
| | - Beat Ernst
- University of Basel, Department of Pharmaceutical Sciences, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Anne Imberty
- Université Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France
| | - Anna Bernardi
- Universita' degli Studi di Milano, Dipartimento di Chimica, via Golgi 19, I-20133, Milano, Italy
| | - Annabelle Varrot
- Université Grenoble Alpes, CNRS, CERMAV, 38000, Grenoble, France
| | - Laura Belvisi
- Universita' degli Studi di Milano, Dipartimento di Chimica, via Golgi 19, I-20133, Milano, Italy
| |
Collapse
|
13
|
Gao C, Stavenhagen K, Eckmair B, McKitrick TR, Mehta AY, Matsumoto Y, McQuillan AM, Hanes MS, Eris D, Baker KJ, Jia N, Wei M, Heimburg-Molinaro J, Ernst B, Cummings RD. Differential recognition of oligomannose isomers by glycan-binding proteins involved in innate and adaptive immunity. Sci Adv 2021; 7:7/24/eabf6834. [PMID: 34108208 PMCID: PMC8189592 DOI: 10.1126/sciadv.abf6834] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Accepted: 04/21/2021] [Indexed: 05/07/2023]
Abstract
The recognition of oligomannose-type glycans in innate and adaptive immunity is elusive due to multiple closely related isomeric glycan structures. To explore the functions of oligomannoses, we developed a multifaceted approach combining mass spectrometry assignments of oligomannose substructures and the development of a comprehensive oligomannose microarray. This defined microarray encompasses both linear and branched glycans, varying in linkages, branching patterns, and phosphorylation status. With this resource, we identified unique recognition of oligomannose motifs by innate immune receptors, including DC-SIGN, L-SIGN, Dectin-2, and Langerin, broadly neutralizing antibodies against HIV gp120, N-acetylglucosamine-1-phosphotransferase, and the bacterial adhesin FimH. The results demonstrate that each protein exhibits a unique specificity to oligomannose motifs and suggest the potential to rationally design inhibitors to selectively block these protein-glycan interactions.
Collapse
Affiliation(s)
- Chao Gao
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
| | - Kathrin Stavenhagen
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Barbara Eckmair
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
- Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Tanya R McKitrick
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Akul Y Mehta
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Yasuyuki Matsumoto
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Alyssa M McQuillan
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Melinda S Hanes
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Deniz Eris
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Kelly J Baker
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Nan Jia
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Mohui Wei
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Jamie Heimburg-Molinaro
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Beat Ernst
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| | - Richard D Cummings
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
14
|
de Matos AM, Blázquez-Sánchez MT, Bento-Oliveira A, de Almeida RFM, Nunes R, Lopes PEM, Machuqueiro M, Cristóvão JS, Gomes CM, Souza CS, El Idrissi IG, Colabufo NA, Diniz A, Marcelo F, Oliveira MC, López Ó, Fernandez-Bolaños JG, Dätwyler P, Ernst B, Ning K, Garwood C, Chen B, Rauter AP. Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease. J Med Chem 2020; 63:11663-11690. [PMID: 32959649 DOI: 10.1021/acs.jmedchem.0c00841] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Despite the rapidly increasing number of patients suffering from type 2 diabetes, Alzheimer's disease, and diabetes-induced dementia, there are no disease-modifying therapies that are able to prevent or block disease progress. In this work, we investigate the potential of nature-inspired glucosylpolyphenols against relevant targets, including islet amyloid polypeptide, glucosidases, and cholinesterases. Moreover, with the premise of Fyn kinase as a paradigm-shifting target in Alzheimer's drug discovery, we explore glucosylpolyphenols as blockers of Aβ-induced Fyn kinase activation while looking into downstream effects leading to Tau hyperphosphorylation. Several compounds inhibit Aβ-induced Fyn kinase activation and decrease pTau levels at 10 μM concentration, particularly the per-O-methylated glucosylacetophloroglucinol and the 4-glucosylcatechol dibenzoate, the latter inhibiting also butyrylcholinesterase and β-glucosidase. Both compounds are nontoxic with ideal pharmacokinetic properties for further development. This work ultimately highlights the multitarget nature, fine structural tuning capacity, and valuable therapeutic significance of glucosylpolyphenols in the context of these metabolic and neurodegenerative disorders.
Collapse
Affiliation(s)
- Ana M de Matos
- Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - M Teresa Blázquez-Sánchez
- Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Andreia Bento-Oliveira
- Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Rodrigo F M de Almeida
- Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Rafael Nunes
- Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal.,Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Pedro E M Lopes
- Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Miguel Machuqueiro
- Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Joana S Cristóvão
- Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Cláudio M Gomes
- Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Cleide S Souza
- Department of Chemistry, The University of Sheffield, Dainton Building, Brook Hill, Sheffield S3 7HF, United Kingdom
| | - Imane G El Idrissi
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "A. Moro", Via Orabona, 4, 70125 Bari, Italy
| | - Nicola A Colabufo
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "A. Moro", Via Orabona, 4, 70125 Bari, Italy
| | - Ana Diniz
- UCIBIO, REQUIMTE, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica 2829-516, Portugal
| | - Filipa Marcelo
- UCIBIO, REQUIMTE, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica 2829-516, Portugal
| | - M Conceição Oliveira
- Mass Spectrometry Facility at CQE, Insituto Superior Técnico, Av. Rovisco Pais, Lisboa 1049-001, Portugal
| | - Óscar López
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Apartado 1203, Sevilla E-41071, Spain
| | - José G Fernandez-Bolaños
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Apartado 1203, Sevilla E-41071, Spain
| | - Philipp Dätwyler
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, Basel CH-4056, Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, Basel CH-4056, Switzerland
| | - Ke Ning
- Department of Neuroscience, Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield S10 2HQ, United Kingdom
| | - Claire Garwood
- Department of Neuroscience, Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield S10 2HQ, United Kingdom
| | - Beining Chen
- Department of Chemistry, The University of Sheffield, Dainton Building, Brook Hill, Sheffield S3 7HF, United Kingdom
| | - Amélia P Rauter
- Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| |
Collapse
|
15
|
Cramer J, Jiang X, Schönemann W, Silbermann M, Zihlmann P, Siegrist S, Fiege B, Jakob RP, Rabbani S, Maier T, Ernst B. Enhancing the enthalpic contribution of hydrogen bonds by solvent shielding. RSC Chem Biol 2020; 1:281-287. [PMID: 34458766 PMCID: PMC8341794 DOI: 10.1039/d0cb00108b] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Accepted: 08/19/2020] [Indexed: 11/21/2022] Open
Abstract
In biological systems, polar interactions are heavily burdened by high desolvation penalties resulting from strong solute-solvent interactions. As a consequence thereof, enthalpic contributions of hydrogen bonds to the free energy of binding are severely diminished. However, this effect is strongly attenuated for interactions within solvent-shielded areas of proteins. In microcalorimetric experiments, we show that the bacterial lectin FimH utilizes conformational adaptions to effectively shield its binding site from solvent. The transition into a lower dielectric environment results in an enthalpic benefit of approximately -13 kJ mol-1 for mannoside binding. However, this effect can be abrogated, if the hydrogen bond network within the binding site is disturbed by deoxygenation of the ligand. Conformational adaption leading to reduced local dielectric constants could represent a general mechanism for proteins to enable enthalpy-driven recognition of polar ligands.
Collapse
Affiliation(s)
- Jonathan Cramer
- Institute of Molecular Pharmacy, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Xiaohua Jiang
- Institute of Molecular Pharmacy, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Wojciech Schönemann
- Institute of Molecular Pharmacy, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Marleen Silbermann
- Institute of Molecular Pharmacy, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Pascal Zihlmann
- Institute of Molecular Pharmacy, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Stefan Siegrist
- Institute of Molecular Pharmacy, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Brigitte Fiege
- Institute of Molecular Pharmacy, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Roman Peter Jakob
- Institute of Structural Biology, University of Basel Klingelbergstrasse 70 4056 Basel Switzerland
| | - Said Rabbani
- Institute of Molecular Pharmacy, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Timm Maier
- Institute of Structural Biology, University of Basel Klingelbergstrasse 70 4056 Basel Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| |
Collapse
|
16
|
Kroezen BS, Conti G, Girardi B, Cramer J, Jiang X, Rabbani S, Müller J, Kokot M, Luisoni E, Ricklin D, Schwardt O, Ernst B. A Potent Mimetic of the Siglec‐8 Ligand 6’‐Sulfo‐Sialyl Lewis
x. ChemMedChem 2020. [DOI: 10.1002/cmdc.202000649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Blijke S. Kroezen
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Gabriele Conti
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Benedetta Girardi
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Jonathan Cramer
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Xiaohua Jiang
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Said Rabbani
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Jennifer Müller
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Maja Kokot
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Enrico Luisoni
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Daniel Ricklin
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Oliver Schwardt
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Beat Ernst
- Molecular Pharmacy Group, Department of Pharmaceutical Sciences University of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| |
Collapse
|
17
|
Kroezen BS, Conti G, Girardi B, Cramer J, Jiang X, Rabbani S, Müller J, Kokot M, Luisoni E, Ricklin D, Schwardt O, Ernst B. A Potent Mimetic of the Siglec-8 Ligand 6'-Sulfo-Sialyl Lewis x. ChemMedChem 2020; 15:1706-1719. [PMID: 32744401 DOI: 10.1002/cmdc.202000417] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Indexed: 12/15/2022]
Abstract
Siglecs are members of the immunoglobulin gene family containing sialic acid binding N-terminal domains. Among them, Siglec-8 is expressed on various cell types of the immune system such as eosinophils, mast cells and weakly on basophils. Cross-linking of Siglec-8 with monoclonal antibodies triggers apoptosis in eosinophils and inhibits degranulation of mast cells, making Siglec-8 a promising target for the treatment of eosinophil- and mast cell-associated diseases such as asthma. The tetrasaccharide 6'-sulfo-sialyl Lewisx has been identified as a specific Siglec-8 ligand in glycan array screening. Here, we describe an extended study enlightening the pharmacophores of 6'-sulfo-sialyl Lewisx and the successful development of a high-affinity mimetic. Retaining the neuraminic acid core, the introduction of a carbocyclic mimetic of the Gal moiety and a sulfonamide substituent in the 9-position gave a 20-fold improved binding affinity. Finally, the residence time, which usually is the Achilles tendon of carbohydrate/lectin interactions, could be improved.
Collapse
Affiliation(s)
- Blijke S Kroezen
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Gabriele Conti
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Benedetta Girardi
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Jonathan Cramer
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Xiaohua Jiang
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Said Rabbani
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Jennifer Müller
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Maja Kokot
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Enrico Luisoni
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Daniel Ricklin
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Oliver Schwardt
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Beat Ernst
- Molecular Pharmacy Group Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| |
Collapse
|
18
|
Scharf B, Schmidt TJ, Rabbani S, Stork C, Dobrindt U, Sendker J, Ernst B, Hensel A. Antiadhesive natural products against uropathogenic E. coli: What can we learn from cranberry extract? J Ethnopharmacol 2020; 257:112889. [PMID: 32311481 DOI: 10.1016/j.jep.2020.112889] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 04/14/2020] [Accepted: 04/14/2020] [Indexed: 06/11/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Extracts from Cranberry fruits (Vaccinium macrocarpon) are traditionally used against urinary tract infections, mainly due to antiadhesive activity against uropathogenic E. coli (UPEC), but the exact mode of action and compounds, responsible for the activity, are unknown. AIM OF THE STUDY i. To investigate if cranberry extract acts only by a single component or must be assessed as a multi-active-compound preparation; ii to screen isolated cranberry-related natural products under in vitro conditions to pinpoint natural products with antiadhesive effects against UPEC, followed by in silico calculations (QSAR) to predict potential antiadhesive compounds; iii. investigations by using urine samples from cranberry treated volunteers for evaluation on the bacterial transcriptome and the mannose-binding side of FimH, iv. to investigate if besides Tamm Horsfall Protein induction in the kidney, the extract acts also directly against UPEC. MATERIAL AND METHODS Antiadhesive activity of 105 compounds was determined by flow cytometric adhesion assay (UPEC UTI89 on T24 bladder cells). Urine samples from 16 volunteers treated with cranberry extract (p.o., 7 days, 900 mg/day) were used for ex vivo testing concerning influence on the bacterial transcriptome (Illumina RNA-seq) and interaction with the mannose binding domain of type-1 fimbriae. RESULTS i. The antiadhesive effect of cranberry extract cannot be attributed to a single compound or to a single fraction. ii. Unglycosylated flavones and flavonols with bulky substitution of the B ring contribute to the antiadhesive activity. 3'-8″-biflavones and flavolignans (not related to cranberry fruits) were identified as potent antiadhesive compounds against UPEC. iii. QSAR yielded a model with good statistical performance and sufficient internal and external predictive ability. iv. Urine samples from male cranberry-treated volunteers indicated significant interaction with the mannose binding domain of type-1 fimbriae, which correlated with the amount of Tamm-Horsfall Protein in the test samples. v Cranberry extract did not influence the UPEC transcriptome; gene expression of bacterial adhesins (P-, S-fimbrae, curli) was not influenced by the urine samples, while a slight, but non-significant upregulation of type 1 fimbriae was observed. CONCLUSIONS B-ring substituted flavones and flavonols from cranberry contribute to the antiadhesive activity against UPEC by inhibition of the FimH-mediated interaction with the host cell bladder epithelium.
Collapse
Affiliation(s)
- Birte Scharf
- University of Münster, Institute of Pharmaceutical Biology and Phytochemistry, Münster, Germany
| | - Thomas J Schmidt
- University of Münster, Institute of Pharmaceutical Biology and Phytochemistry, Münster, Germany
| | - Said Rabbani
- University of Basel, Department Pharmaceutical Sciences, Molecular Pharmacy, Basel, Switzerland
| | - Christoph Stork
- University Hospital Münster, Institute of Hygiene, Münster, Germany
| | - Ulrich Dobrindt
- University Hospital Münster, Institute of Hygiene, Münster, Germany
| | - Jandirk Sendker
- University of Münster, Institute of Pharmaceutical Biology and Phytochemistry, Münster, Germany
| | - Beat Ernst
- University of Basel, Department Pharmaceutical Sciences, Molecular Pharmacy, Basel, Switzerland
| | - Andreas Hensel
- University of Münster, Institute of Pharmaceutical Biology and Phytochemistry, Münster, Germany.
| |
Collapse
|
19
|
Aliu B, Demeestere D, Seydoux E, Boucraut J, Delmont E, Brodovitch A, Oberholzer T, Attarian S, Théaudin M, Tsouni P, Kuntzer T, Derfuss T, Steck AJ, Ernst B, Herrendorff R, Hänggi P. Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen-specific glycopolymer. J Neurochem 2020; 154:486-501. [PMID: 32270492 PMCID: PMC7497077 DOI: 10.1111/jnc.15021] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Revised: 03/11/2020] [Accepted: 03/18/2020] [Indexed: 12/13/2022]
Abstract
Anti‐myelin‐associated glycoprotein (MAG) neuropathy is a disabling autoimmune peripheral neuropathy that is caused by circulating monoclonal IgM autoantibodies directed against the human natural killer‐1 (HNK‐1) epitope. This carbohydrate epitope is highly expressed on adhesion molecules such as MAG, a glycoprotein present in myelinated nerves. We previously showed the therapeutic potential of the glycopolymer poly(phenyl disodium 3‐O‐sulfo‐β‐d‐glucopyranuronate)‐(1→3)‐β‐d‐galactopyranoside (PPSGG) in selectively neutralizing anti‐MAG IgM antibodies in an immunological mouse model and ex vivo with sera from anti‐MAG neuropathy patients. PPSGG is composed of a biodegradable backbone that multivalently presents a mimetic of the HNK‐1 epitope. In this study, we further explored the pharmacodynamic properties of the glycopolymer and its ability to inhibit the binding of anti‐MAG IgM to peripheral nerves. The polymer selectively bound anti‐MAG IgM autoantibodies and prevented the binding of patients’ anti‐MAG IgM antibodies to myelin of non‐human primate sciatic nerves. Upon PPSGG treatment, neither activation nor inhibition of human and murine peripheral blood mononuclear cells nor alteration of systemic inflammatory markers was observed in mice or ex vivo in human peripheral blood mononuclear cells. Intravenous injections of PPSGG to mice immunized against the HNK‐1 epitope removed anti‐MAG IgM antibodies within less than 1 hr, indicating a fast and efficient mechanism of action as compared to a B‐cell depletion with anti‐CD20. In conclusion, these observations corroborate the therapeutic potential of PPSGG for an antigen‐specific treatment of anti‐MAG neuropathy. ![]()
Read the Editorial Highlight for this article on page 465.
Collapse
Affiliation(s)
- Butrint Aliu
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | - Delphine Demeestere
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | | | - José Boucraut
- Immunology laboratory, AP-HM, Marseille, France.,INT, UMR CNRS 7289, Aix-Marseille University, Marseille, France
| | - Emilien Delmont
- Center for Neuromuscular Disorders and ALS La Timone Hospital, AP-HM, Marseille, France
| | - Alexandre Brodovitch
- Immunology laboratory, AP-HM, Marseille, France.,Center for Neuromuscular Disorders and ALS La Timone Hospital, AP-HM, Marseille, France
| | | | - Shahram Attarian
- Center for Neuromuscular Disorders and ALS La Timone Hospital, AP-HM, Marseille, France
| | - Marie Théaudin
- Nerve-Muscle Unit, Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Pinelopi Tsouni
- Nerve-Muscle Unit, Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Thierry Kuntzer
- Nerve-Muscle Unit, Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Tobias Derfuss
- Clinic of Neurology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Andreas J Steck
- Clinic of Neurology, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | - Ruben Herrendorff
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.,Polyneuron Pharmaceuticals AG, Basel, Switzerland
| | - Pascal Hänggi
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.,Polyneuron Pharmaceuticals AG, Basel, Switzerland
| |
Collapse
|
20
|
Abstract
ZusammenfassungEntwicklungsförderung der Sprache, sei es zu Hause, in Institutionen oder in der Sprachtherapie, erfordert die frühe Erfassung der Sprachkompetenz möglichst aller Kinder im Rahmen präventiver Untersuchungen (wie z. B. den kinderärztlichen Vorsorgeuntersuchungen). Der vorliegende Beitrag fasst dasjenige Wissen zusammen, das der Kinderarzt haben muss, um Kinder mit Risiken für Spracherwerbsverzögerungen oder manifesten Störungen der Sprache in der Praxis zuverlässig erkennen zu können. Außerdem werden die wichtigsten Maßnahmen bei Kindern mit sprachlichen Schwierigkeiten erläutert.
Collapse
|
21
|
de Matos AM, Martins A, Man T, Evans D, Walter M, Oliveira MC, López Ó, Fernandez-Bolaños JG, Dätwyler P, Ernst B, Macedo MP, Contino M, Colabufo NA, Rauter AP. Design and Synthesis of CNS-targeted Flavones and Analogues with Neuroprotective Potential Against H 2O 2- and Aβ 1-42-Induced Toxicity in SH-SY5Y Human Neuroblastoma Cells. Pharmaceuticals (Basel) 2019; 12:ph12020098. [PMID: 31234364 PMCID: PMC6630837 DOI: 10.3390/ph12020098] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 06/05/2019] [Accepted: 06/06/2019] [Indexed: 01/15/2023] Open
Abstract
With the lack of available drugs able to prevent the progression of Alzheimer’s disease (AD), the discovery of new neuroprotective treatments able to rescue neurons from cell injury is presently a matter of extreme importance and urgency. Here, we were inspired by the widely reported potential of natural flavonoids to build a library of novel flavones, chromen-4-ones and their C-glucosyl derivatives, and to explore their ability as neuroprotective agents with suitable pharmacokinetic profiles. All compounds were firstly evaluated in a parallel artificial membrane permeability assay (PAMPA) to assess their effective permeability across biological membranes, namely the blood-brain barrier (BBB). With this test, we aimed not only at assessing if our candidates would be well-distributed, but also at rationalizing the influence of the sugar moiety on the physicochemical properties. To complement our analysis, logD7.4 was determined. From all screened compounds, the p-morpholinyl flavones stood out for their ability to fully rescue SH-SY5Y human neuroblastoma cells against both H2O2- and Aβ1-42-induced cell death. Cholinesterase inhibition was also evaluated, and modest inhibitory activities were found. This work highlights the potential of C-glucosylflavones as neuroprotective agents, and presents the p-morpholinyl C-glucosylflavone 37, which did not show any cytotoxicity towards HepG2 and Caco-2 cells at 100 μM, as a new lead structure for further development against AD.
Collapse
Affiliation(s)
- Ana M de Matos
- Center of Chemistry and Biochemistry, Faculdade de Ciências, Universidade de Lisboa, Ed. C8, Campo Grande, 1749-016 Lisboa, Portugal.
- Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Ed. C8, Campo Grande, 1749-016 Lisboa, Portugal.
- MEDIR: Metabolic Disorders, CEDOC Chronic Diseases, Nova Medical School, Campus Sant'Ana, Rua Câmara Pestana, 6, Lab 3.8, 1150-082 Lisboa, Portugal.
| | - Alice Martins
- Center of Chemistry and Biochemistry, Faculdade de Ciências, Universidade de Lisboa, Ed. C8, Campo Grande, 1749-016 Lisboa, Portugal.
| | - Teresa Man
- Department of Chemistry, Erl Wood Manor, Eli Lilly, Windlesham, Surrey GU20 6PH, UK.
| | - David Evans
- Department of Chemistry, Erl Wood Manor, Eli Lilly, Windlesham, Surrey GU20 6PH, UK.
| | - Magnus Walter
- Abbvie Germany, Knollstr. 51, 67061 Ludwigshafen, Germany.
| | - Maria Conceição Oliveira
- Centro de Química Estrutural, Instiuto Superior Técnico, Ulisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal.
| | - Óscar López
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Apartado 1203, E-41071 Sevilla, Spain.
| | - José G Fernandez-Bolaños
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Apartado 1203, E-41071 Sevilla, Spain.
| | - Philipp Dätwyler
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland.
| | - Beat Ernst
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland.
| | - M Paula Macedo
- MEDIR: Metabolic Disorders, CEDOC Chronic Diseases, Nova Medical School, Campus Sant'Ana, Rua Câmara Pestana, 6, Lab 3.8, 1150-082 Lisboa, Portugal.
- Department of Medical Sciences, IBIMED, Universidade de Aveiro, 3810-193 Aveiro, Portugal.
- APDP-ERC, APDP-Diabetes Portugal, Rua do Salitre, Nº 118-120, 1250-203 Lisboa, Portugal.
| | - Marialessandra Contino
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari/Biofordrug, Via Edoardo Orabona, 4-70125 Bari, Italy.
| | - Nicola A Colabufo
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari/Biofordrug, Via Edoardo Orabona, 4-70125 Bari, Italy.
| | - Amélia P Rauter
- Center of Chemistry and Biochemistry, Faculdade de Ciências, Universidade de Lisboa, Ed. C8, Campo Grande, 1749-016 Lisboa, Portugal.
- Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Ed. C8, Campo Grande, 1749-016 Lisboa, Portugal.
| |
Collapse
|
22
|
Dias C, Matos AM, Blásquez-Sanchez MT, Calado P, Martins A, Dätwyler P, Ernst B, Macedo MP, Colabufo N, Rauter AP. 2-Deoxyglycosylation towards more effective and bioavailable neuroprotective molecules inspired by nature. PURE APPL CHEM 2019. [DOI: 10.1515/pac-2019-0303] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Abstract
The neuroprotective role of natural polyphenols is well established but phenolics poor water solubility affects their bioavailability and bioactivity. Aiming to overcome this issue, we were encouraged to investigate the 2-deoxyglycosylation of natural or nature inspired neuroprotective molecules, using glycals as easily accessed glycosyl donors. This robust methodology allowed the generation of a set of new resveratrol and caffeic acid ester glycosides, envisioning more effective and bioavailable compounds. Resveratrol 2-deoxyglycosides were more effective at protecting the neuronal cells from peroxide-induced cytotoxicity than resveratrol itself, while the caffeic acid ester glycoside also showed extraordinary neuroprotection activity. Coefficient partition measurements demonstrated the moderate lipophilicity of resveratrol glycosides, which Log D values are typical of a central nervous system (CNS) drug and ideal for blood-brain barrier (BBB) penetration. Passive permeation assessed by the parallel artificial membrane permeability assay (PAMPA) revealed that 2,6-dideoxy-l-arabino-hexopyranosides were more effective than 2-deoxy-d-arabino-hexopyranosides. The lack of toxicity of the neuroprotective glycosides and their promising physicochemical properties revealed the usefulness of sugar coupling towards the modulation of natural product properties and bioactivity.
Collapse
Affiliation(s)
- Catarina Dias
- Centro de Química e Bioquímica, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
- Centro de Química Estrutural, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
| | - Ana M. Matos
- Centro de Química e Bioquímica, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
- Centro de Química Estrutural, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
- Centro de Estudos de Doenҫas Crónicas (CEDOC), Chronic Disease Research Center, NOVA Medical School/Faculdade de Ciências Médicas , Universidade Nova de Lisboa , Lisboa , Portugal
| | - Maria T. Blásquez-Sanchez
- Centro de Química e Bioquímica, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
- Centro de Química Estrutural, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
| | - Patrícia Calado
- Centro de Química e Bioquímica, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
- Centro de Química Estrutural, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
| | - Alice Martins
- Centro de Química e Bioquímica, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
- Centro de Química Estrutural, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
| | - Philipp Dätwyler
- Department of Pharmaceutical Sciences, Pharmacenter , University of Basel , Klingelbergstrasse 50 , CH-4056 Basel , Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences, Pharmacenter , University of Basel , Klingelbergstrasse 50 , CH-4056 Basel , Switzerland
| | - M. Paula Macedo
- Centro de Estudos de Doenҫas Crónicas (CEDOC), Chronic Disease Research Center, NOVA Medical School/Faculdade de Ciências Médicas , Universidade Nova de Lisboa , Lisboa , Portugal
- Department of Medical Sciences, Institute of Biomedicine , University of Aveiro , Aveiro , Portugal
| | - Nicola Colabufo
- Università degli Studi di Bari, Biofordrug , Via Edoardo Orabona, 4 , 70125 Bari , Italy
| | - Amélia P. Rauter
- Centro de Química e Bioquímica, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
- Centro de Química Estrutural, Faculdade de Ciências , Universidade de Lisboa, Ed. C8, Campo Grande , 1749-016 Lisboa , Portugal
| |
Collapse
|
23
|
Cramer J, Sager CP, Ernst B. Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group. J Med Chem 2019; 62:8915-8930. [DOI: 10.1021/acs.jmedchem.9b00179] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Jonathan Cramer
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Christoph P. Sager
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| |
Collapse
|
24
|
Frei P, Silbermann M, Mühlethaler T, Jiang X, Schwardt O, Hevey R, Ernst B. Comparison of affinity ranking by target-directed dynamic combinatorial chemistry and surface plasmon resonance. ARKIVOC 2019. [DOI: 10.24820/ark.5550190.p010.913] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
25
|
Schönemann W, Cramer J, Mühlethaler T, Fiege B, Silbermann M, Rabbani S, Dätwyler P, Zihlmann P, Jakob RP, Sager CP, Smieško M, Schwardt O, Maier T, Ernst B. Front Cover: Improvement of Aglycone π‐Stacking Yields Nanomolar to Sub‐nanomolar FimH Antagonists (ChemMedChem 7/2019). ChemMedChem 2019. [DOI: 10.1002/cmdc.201900177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Wojciech Schönemann
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Jonathan Cramer
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Tobias Mühlethaler
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Brigitte Fiege
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Marleen Silbermann
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Said Rabbani
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Philipp Dätwyler
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Pascal Zihlmann
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Roman P. Jakob
- Department Biozentrum, Focal Area Structural BiologyUniversity of Basel Klingelbergstrasse 70 4056 Basel Switzerland
| | - Christoph P. Sager
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Martin Smieško
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Oliver Schwardt
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Timm Maier
- Department Biozentrum, Focal Area Structural BiologyUniversity of Basel Klingelbergstrasse 70 4056 Basel Switzerland
| | - Beat Ernst
- Department of Pharmaceutical SciencesUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| |
Collapse
|
26
|
Schönemann W, Cramer J, Mühlethaler T, Fiege B, Silbermann M, Rabbani S, Dätwyler P, Zihlmann P, Jakob RP, Sager CP, Smieško M, Schwardt O, Maier T, Ernst B. Improvement of Aglycone π-Stacking Yields Nanomolar to Sub-nanomolar FimH Antagonists. ChemMedChem 2019; 14:749-757. [PMID: 30710416 DOI: 10.1002/cmdc.201900051] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Indexed: 11/08/2022]
Abstract
Antimicrobial resistance has become a serious concern for the treatment of urinary tract infections. In this context, an anti-adhesive approach targeting FimH, a bacterial lectin enabling the attachment of E. coli to host cells, has attracted considerable interest. FimH can adopt a low/medium-affinity state in the absence and a high-affinity state in the presence of shear forces. Until recently, mostly the high-affinity state has been investigated, despite the fact that a therapeutic antagonist should bind predominantly to the low-affinity state. In this communication, we demonstrate that fluorination of biphenyl α-d-mannosides leads to compounds with perfect π-π stacking interactions with the tyrosine gate of FimH, yielding low nanomolar to sub-nanomolar KD values for the low- and high-affinity states, respectively. The face-to-face alignment of the perfluorinated biphenyl group of FimH ligands and Tyr48 was confirmed by crystal structures as well as 1 H,15 N-HSQC NMR analysis. Finally, fluorination improves pharmacokinetic parameters predictive for oral availability.
Collapse
Affiliation(s)
- Wojciech Schönemann
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Jonathan Cramer
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Tobias Mühlethaler
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Brigitte Fiege
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Marleen Silbermann
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Said Rabbani
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Philipp Dätwyler
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Pascal Zihlmann
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Roman P Jakob
- Department Biozentrum, Focal Area Structural Biology, University of Basel, Klingelbergstrasse 70, 4056, Basel, Switzerland
| | - Christoph P Sager
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Martin Smieško
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Oliver Schwardt
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Timm Maier
- Department Biozentrum, Focal Area Structural Biology, University of Basel, Klingelbergstrasse 70, 4056, Basel, Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| |
Collapse
|
27
|
Ertz-Archambault N, Rogoff L, Kosiorek H, Ernst B, Anderson K, Pockaj B, Gray R, Northfelt D. Abstract P1-11-13: Depomedroxyprogesterone therapy for hot flashes in survivors of ER-expressing breast cancer: Impact on recurrence and survival. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-11-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Survivors of ER-expressing operable breast cancer (ER+BC) generally do not receive hormone replacement therapy for menopausal symptoms due to concern about provoking recurrence of disease. Single dose depomedroxyprogesterone acetate (MPA) 400 mg IM has previously been shown (Loprinzi CL, et al. J Clin Oncol 2006;24:1409) to be the most effective non-estrogen therapy available for menopausal hot flashes (HF) but long-term evidence of safety in survivors of ER+BC is lacking.
Methods
Consecutive patients previously diagnosed with ER+BC who received MPA for HF between January 2007 and December 2012 were retrospectively identified in the breast cancer patient database at Mayo Clinic Arizona. Medical records were audited for breast cancer outcomes in these cases and in contemporaneous control patients with ER+BC who did not receive MPA, matched for age, stage of disease, and year of diagnosis. Statistical comparisons of local-regional recurrence and event-free survival were performed.
Results
92 patients who received MPA were identified and matched 1:1 with contemporaneous controls. Median follow-up duration was 5.7 years in cases and 4.5 years in controls. Estimated local-regional recurrence free survival at 10 years was 85% (95% CI, 72-100%) in cases and 95% (95% CI, 86-100%) in controls. Matched pairs hazard ratio was 1.0 (95% CI, 0.06-16.0) for local-regional recurrence free survival. Estimated event-free survival at 10 years was 81% (95% CI, 69-97%) in cases and 76% (95% CI, 64-92%) in controls. Matched pairs hazard ratio was 0.38 (95% CI, 0.10-1.41) for event-free survival. The majority (77%) of case patients experienced satisfactory relief of hot flashes from MPA injection.
Conclusion
In this retrospective case-control study we were unable to identify a detrimental effect of MPA therapy for HF in survivors of ER+BC. MPA may be acceptable for management of HF in this population.
Citation Format: Ertz-Archambault N, Rogoff L, Kosiorek H, Ernst B, Anderson K, Pockaj B, Gray R, Northfelt D. Depomedroxyprogesterone therapy for hot flashes in survivors of ER-expressing breast cancer: Impact on recurrence and survival [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-13.
Collapse
Affiliation(s)
| | - L Rogoff
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Florida, Jacksonville, FL
| | - H Kosiorek
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Florida, Jacksonville, FL
| | - B Ernst
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Florida, Jacksonville, FL
| | - K Anderson
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Florida, Jacksonville, FL
| | - B Pockaj
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Florida, Jacksonville, FL
| | - R Gray
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Florida, Jacksonville, FL
| | - D Northfelt
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Florida, Jacksonville, FL
| |
Collapse
|
28
|
McDonald BR, Contente-Cuomo T, Sammut SJ, Ernst B, Odenheimer-Bergman A, Perdigones N, Chin SF, Farooq M, Cronin PA, Anderson KS, Kosiorek H, Northfelt D, McCullough A, Patel B, Caldas C, Pockaj B, Murtaza M. Abstract P4-01-21: Multiplexed targeted digital sequencing of circulating tumor DNA to detect minimal residual disease in early and locally advanced breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-01-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Circulating tumor DNA (ctDNA) analysis holds potential for minimal residual disease (MRD) detection in early stage breast cancer. However, sensitivity for MRD is limited due to low ctDNA levels in early stage patients and limited blood volumes. Loss of input DNA during library preparation, limited multiplexing or low sensitivity of current molecular methods further limit accuracy. To address this gap, we have developed TARgeted DIgital Sequencing (TARDIS), a novel method for simultaneous analysis of multiple patient-specific mutations in plasma DNA.
Methods:
Using tumor exome sequencing, we identify and prioritize somatic founder mutations, design nested primers and evaluate them for multiplex performance. Using 5-10 ng input plasma DNA, we perform 1) targeted linear pre-amplification to improve downstream molecular conversion, 2) single-stranded adapter ligation to incorporate unique molecular identifiers (UMIs) and 3) targeted PCR to prepare sequencing-ready libraries. The resulting sequencing reads have fixed target-specific ends and variable ligation ends. We utilize fragment size and UMIs to group sequencing reads into read families. To ensure specificity, we require targeted mutations are supported by 2 or more read families.
Results:
To assess analytical performance, we targeted 8 mutations in cell-free DNA reference samples with 0.25%-2% mutation allele fractions (AFs). Precision across 7-16 replicates at each AF level agreed with expectations of Poisson distribution, demonstrating effective analysis of ˜70% of input DNA. At 2%, 1%, 0.5% and 0.25% AFs, variant-level sensitivity was 96.4%, 96.4%, 91.1% and 65.8%, approaching the theoretical limit given input DNA. At 0.25% AF, 3-7 mutations were detected per sample, achieving 100% sample-level sensitivity. In 16 wild-type replicates, no targeted mutations were called (100% specificity). Averaging multiple mutations improved precision in sample-level AF estimates. Mean AFs from 8 mutations for the 2% sample were 2.34%-2.80% (5.8% CV).
In 6 patients with breast cancer treated with neoadjuvant therapy (NAT), we analyzed 8-18 patient-specific mutations (mean 11.8). Before treatment, ctDNA was detected in 5/6 patients at mean AFs of 0.02%-1.19% (mean 0.40%), supported by 2-10 mutations (mean 5.6). Of these 5 patients, 4 had residual disease after NAT and ctDNA was detected pre-operatively or during NAT in 3/4 patients. 1 patient achieved pathological Complete Response and ctDNA was undetectable after NAT.
Conclusions:
Preliminary results suggest TARDIS enables accurate MRD detection after neoadjuvant therapy in patients with early stage breast cancer. On-going work is expanding this analysis to include additional patients and investigate the clinical validity of peri-operative ctDNA monitoring.
Summary of clinical resultsPatientPre-NAT Stage (TNM)SubtypeNo. of Mutations TargetedBaseline ctDNA (AF%, No. of Mutations)ctDNA after or during NAT (AF%, No. of Mutations)Residual Tumor (TNM)1T3 N1ER+ PR+ HER2-8+ (0.02%, 2)-T2 N12T3 N0TNBC12+ (0.29%, 6)+ (0.01%, 1)T1a N03T2 N1TNBC18+ (1.19%, 10)+ (0.01%, 1)T1mi N04T3 N1TNBC10+ (0.02%, 3)+ (0.05%, 3)T3 N15T2 N0TNBC9+ (0.46%, 7)-pathCR6T1c N1TNBC14--pathCR
Citation Format: McDonald BR, Contente-Cuomo T, Sammut S-J, Ernst B, Odenheimer-Bergman A, Perdigones N, Chin S-F, Farooq M, Cronin PA, Anderson KS, Kosiorek H, Northfelt D, McCullough A, Patel B, Caldas C, Pockaj B, Murtaza M. Multiplexed targeted digital sequencing of circulating tumor DNA to detect minimal residual disease in early and locally advanced breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-01-21.
Collapse
Affiliation(s)
- BR McDonald
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - T Contente-Cuomo
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - S-J Sammut
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - B Ernst
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - A Odenheimer-Bergman
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - N Perdigones
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - S-F Chin
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - M Farooq
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - PA Cronin
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - KS Anderson
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - H Kosiorek
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - D Northfelt
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - A McCullough
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - B Patel
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - C Caldas
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - B Pockaj
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - M Murtaza
- Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| |
Collapse
|
29
|
Sauer MM, Jakob RP, Luber T, Canonica F, Navarra G, Ernst B, Unverzagt C, Maier T, Glockshuber R. Binding of the Bacterial Adhesin FimH to Its Natural, Multivalent High-Mannose Type Glycan Targets. J Am Chem Soc 2018; 141:936-944. [PMID: 30543411 DOI: 10.1021/jacs.8b10736] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Multivalent carbohydrate-lectin interactions at host-pathogen interfaces play a crucial role in the establishment of infections. Although competitive antagonists that prevent pathogen adhesion are promising antimicrobial drugs, the molecular mechanisms underlying these complex adhesion processes are still poorly understood. Here, we characterize the interactions between the fimbrial adhesin FimH from uropathogenic Escherichia coli strains and its natural high-mannose type N-glycan binding epitopes on uroepithelial glycoproteins. Crystal structures and a detailed kinetic characterization of ligand-binding and dissociation revealed that the binding pocket of FimH evolved such that it recognizes the terminal α(1-2)-, α(1-3)-, and α(1-6)-linked mannosides of natural high-mannose type N-glycans with similar affinity. We demonstrate that the 2000-fold higher affinity of the domain-separated state of FimH compared to its domain-associated state is ligand-independent and consistent with a thermodynamic cycle in which ligand-binding shifts the association equilibrium between the FimH lectin and the FimH pilin domain. Moreover, we show that a single N-glycan can bind up to three molecules of FimH, albeit with negative cooperativity, so that a molar excess of accessible N-glycans over FimH on the cell surface favors monovalent FimH binding. Our data provide pivotal insights into the adhesion properties of uropathogenic Escherichia coli strains to their target receptors and a solid basis for the development of effective FimH antagonists.
Collapse
Affiliation(s)
- Maximilian M Sauer
- Institute of Molecular Biology & Biophysics , ETH Zurich , Otto-Stern-Weg 5 , CH-8093 Zurich , Switzerland
| | - Roman P Jakob
- Biozentrum , University of Basel , Klingelbergstrasse 50/70 , CH-4056 Basel , Switzerland
| | - Thomas Luber
- Bioorganische Chemie , University of Bayreuth , D-95440 Bayreuth , Germany
| | - Fabia Canonica
- Institute of Molecular Biology & Biophysics , ETH Zurich , Otto-Stern-Weg 5 , CH-8093 Zurich , Switzerland
| | - Giulio Navarra
- Department of Pharmaceutical Sciences , University of Basel , Klingelbergstrasse 50 , CH-4056 Basel , Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences , University of Basel , Klingelbergstrasse 50 , CH-4056 Basel , Switzerland
| | - Carlo Unverzagt
- Bioorganische Chemie , University of Bayreuth , D-95440 Bayreuth , Germany
| | - Timm Maier
- Biozentrum , University of Basel , Klingelbergstrasse 50/70 , CH-4056 Basel , Switzerland
| | - Rudi Glockshuber
- Institute of Molecular Biology & Biophysics , ETH Zurich , Otto-Stern-Weg 5 , CH-8093 Zurich , Switzerland
| |
Collapse
|
30
|
Affiliation(s)
- Priska Frei
- Institute of Molecular Pharmacy, PharmacenterUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Rachel Hevey
- Institute of Molecular Pharmacy, PharmacenterUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, PharmacenterUniversity of Basel Klingelbergstrasse 50 4056 Basel Switzerland
| |
Collapse
|
31
|
Zihlmann P, Silbermann M, Sharpe T, Jiang X, Mühlethaler T, Jakob RP, Rabbani S, Sager CP, Frei P, Pang L, Maier T, Ernst B. KinITC-One Method Supports both Thermodynamic and Kinetic SARs as Exemplified on FimH Antagonists. Chemistry 2018; 24:13049-13057. [PMID: 29939458 DOI: 10.1002/chem.201802599] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Revised: 06/21/2018] [Indexed: 11/09/2022]
Abstract
Affinity data, such as dissociation constants (KD ) or inhibitory concentrations (IC50 ), are widely used in drug discovery. However, these parameters describe an equilibrium state, which is often not established in vivo due to pharmacokinetic effects and they are therefore not necessarily sufficient for evaluating drug efficacy. More accurate indicators for pharmacological activity are the kinetics of binding processes, as they shed light on the rate of formation of protein-ligand complexes and their half-life. Nonetheless, although highly desirable for medicinal chemistry programs, studies on structure-kinetic relationships (SKR) are still rare. With the recently introduced analytical tool kinITC this situation may change, since not only thermodynamic but also kinetic information of the binding process can be deduced from isothermal titration calorimetry (ITC) experiments. Using kinITC, ITC data of 29 mannosides binding to the bacterial adhesin FimH were re-analyzed to make their binding kinetics accessible. To validate these kinetic data, surface plasmon resonance (SPR) experiments were conducted. The kinetic analysis by kinITC revealed that the nanomolar affinities of the FimH antagonists arise from both (i) an optimized interaction between protein and ligand in the bound state (reduced off-rate constant koff ) and (ii) a stabilization of the transition state or a destabilization of the unbound state (increased on-rate constant kon ). Based on congeneric ligand modifications and structural input from co-crystal structures, a strong relationship between the formed hydrogen-bond network and koff could be concluded, whereas electrostatic interactions and conformational restrictions upon binding were found to have mainly an impact on kon .
Collapse
Affiliation(s)
- Pascal Zihlmann
- Institute of Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Marleen Silbermann
- Institute of Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Timothy Sharpe
- Biophysics Facility, Biozentrum, University of Basel, Klingelbergstrasse 70, 4056, Basel, Switzerland
| | - Xiaohua Jiang
- Institute of Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Tobias Mühlethaler
- Institute of Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Roman P Jakob
- Focal Area Structural Biology, Biozentrum, University of Basel, Klingelbergstrasse 70, 4056, Basel, Switzerland
| | - Said Rabbani
- Institute of Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Christoph P Sager
- Institute of Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Priska Frei
- Institute of Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Lijuan Pang
- Institute of Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Timm Maier
- Focal Area Structural Biology, Biozentrum, University of Basel, Klingelbergstrasse 70, 4056, Basel, Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| |
Collapse
|
32
|
Guo T, Dätwyler P, Demina E, Richards MR, Ge P, Zou C, Zheng R, Fougerat A, Pshezhetsky AV, Ernst B, Cairo CW. Selective Inhibitors of Human Neuraminidase 3. J Med Chem 2018; 61:1990-2008. [PMID: 29425031 DOI: 10.1021/acs.jmedchem.7b01574] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Human neuraminidases (NEU) are associated with human diseases including cancer, atherosclerosis, and diabetes. To obtain small molecule inhibitors as research tools for the study of their biological functions, we designed a library of 2-deoxy-2,3-didehydro- N-acetylneuraminic acid (DANA) analogues with modifications at C4 and C9 positions. This library allowed us to discover selective inhibitors targeting the human NEU3 isoenzyme. Our most selective inhibitor for NEU3 has a Ki of 320 ± 40 nM and a 15-fold selectivity over other human neuraminidase isoenzymes. This inhibitor blocks glycolipid processing by NEU3 in vitro. To improve their pharmacokinetic properties, various esters of the best inhibitors were synthesized and evaluated. Finally, we confirmed that our best compounds exhibited selective inhibition of NEU orthologues from murine brain.
Collapse
Affiliation(s)
- Tianlin Guo
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| | - Philipp Dätwyler
- Department of Pharmaceutical Sciences, Pharmacenter , University of Basel , Klingelbergstrasse 50 , CH-4056 Basel , Switzerland
| | - Ekaterina Demina
- Division of Medical Genetics, Sainte-Justine University Hospital Research Center , University of Montreal , Montréal , Quebec H3T 1C5 , Canada
| | - Michele R Richards
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| | - Peng Ge
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| | - Chunxia Zou
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| | - Ruixiang Zheng
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| | - Anne Fougerat
- Division of Medical Genetics, Sainte-Justine University Hospital Research Center , University of Montreal , Montréal , Quebec H3T 1C5 , Canada
| | - Alexey V Pshezhetsky
- Division of Medical Genetics, Sainte-Justine University Hospital Research Center , University of Montreal , Montréal , Quebec H3T 1C5 , Canada
| | - Beat Ernst
- Department of Pharmaceutical Sciences, Pharmacenter , University of Basel , Klingelbergstrasse 50 , CH-4056 Basel , Switzerland
| | - Christopher W Cairo
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| |
Collapse
|
33
|
Rabbani S, Fiege B, Eris D, Silbermann M, Jakob RP, Navarra G, Maier T, Ernst B. Conformational switch of the bacterial adhesin FimH in the absence of the regulatory domain: Engineering a minimalistic allosteric system. J Biol Chem 2018; 293:1835-1849. [PMID: 29180452 PMCID: PMC5798311 DOI: 10.1074/jbc.m117.802942] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Revised: 11/23/2017] [Indexed: 11/06/2022] Open
Abstract
For many biological processes such as ligand binding, enzymatic catalysis, or protein folding, allosteric regulation of protein conformation and dynamics is fundamentally important. One example is the bacterial adhesin FimH, where the C-terminal pilin domain exerts negative allosteric control over binding of the N-terminal lectin domain to mannosylated ligands on host cells. When the lectin and pilin domains are separated under shear stress, the FimH-ligand interaction switches in a so-called catch-bond mechanism from the low- to high-affinity state. So far, it has been assumed that the pilin domain is essential for the allosteric propagation within the lectin domain that would otherwise be conformationally rigid. To test this hypothesis, we generated mutants of the isolated FimH lectin domain and characterized their thermodynamic, kinetic, and structural properties using isothermal titration calorimetry, surface plasmon resonance, nuclear magnetic resonance, and X-ray techniques. Intriguingly, some of the mutants mimicked the conformational and kinetic behaviors of the full-length protein and, even in absence of the pilin domain, conducted the cross-talk between allosteric sites and the mannoside-binding pocket. Thus, these mutants represent a minimalistic allosteric system of FimH, useful for further mechanistic studies and antagonist design.
Collapse
Affiliation(s)
- Said Rabbani
- From the Department of Pharmaceutical Sciences, Pharmacenter of the University of Basel, Klingelbergstrasse 50 and
| | - Brigitte Fiege
- From the Department of Pharmaceutical Sciences, Pharmacenter of the University of Basel, Klingelbergstrasse 50 and
| | - Deniz Eris
- From the Department of Pharmaceutical Sciences, Pharmacenter of the University of Basel, Klingelbergstrasse 50 and
| | - Marleen Silbermann
- From the Department of Pharmaceutical Sciences, Pharmacenter of the University of Basel, Klingelbergstrasse 50 and
| | - Roman Peter Jakob
- the Department Biozentrum, Focal Area Structural Biology, University of Basel, Klingelbergstrasse 70, 4056 Basel, Switzerland
| | - Giulio Navarra
- From the Department of Pharmaceutical Sciences, Pharmacenter of the University of Basel, Klingelbergstrasse 50 and
| | - Timm Maier
- the Department Biozentrum, Focal Area Structural Biology, University of Basel, Klingelbergstrasse 70, 4056 Basel, Switzerland
| | - Beat Ernst
- From the Department of Pharmaceutical Sciences, Pharmacenter of the University of Basel, Klingelbergstrasse 50 and
| |
Collapse
|
34
|
Sager CP, Eriş D, Smieško M, Hevey R, Ernst B. What contributes to an effective mannose recognition domain? Beilstein J Org Chem 2017; 13:2584-2595. [PMID: 29259668 PMCID: PMC5727865 DOI: 10.3762/bjoc.13.255] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Accepted: 11/15/2017] [Indexed: 12/27/2022] Open
Abstract
In general, carbohydrate-lectin interactions are characterized by high specificity but also low affinity. The main reason for the low affinities are desolvation costs, due to the numerous hydroxy groups present on the ligand, together with the typically polar surface of the binding sites. Nonetheless, nature has evolved strategies to overcome this hurdle, most prominently in relation to carbohydrate-lectin interactions of the innate immune system but also in bacterial adhesion, a process key for the bacterium's survival. In an effort to better understand the particular characteristics, which contribute to a successful carbohydrate recognition domain, the mannose-binding sites of six C-type lectins and of three bacterial adhesins were analyzed. One important finding is that the high enthalpic penalties caused by desolvation can only be compensated for by the number and quality of hydrogen bonds formed by each of the polar hydroxy groups engaged in the binding process. In addition, since mammalian mannose-binding sites are in general flat and solvent exposed, the half-lives of carbohydrate-lectin complexes are rather short since water molecules can easily access and displace the ligand from the binding site. In contrast, the bacterial lectin FimH benefits from a deep mannose-binding site, leading to a substantial improvement in the off-rate. Together with both a catch-bond mechanism (i.e., improvement of affinity under shear stress) and multivalency, two methods commonly utilized by pathogens, the affinity of the carbohydrate-FimH interaction can be further improved. Including those just described, the various approaches explored by nature to optimize selectivity and affinity of carbohydrate-lectin interactions offer interesting therapeutic perspectives for the development of carbohydrate-based drugs.
Collapse
Affiliation(s)
- Christoph P Sager
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| | - Deniz Eriş
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| | - Martin Smieško
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| | - Rachel Hevey
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| |
Collapse
|
35
|
Sager CP, Fiege B, Zihlmann P, Vannam R, Rabbani S, Jakob RP, Preston RC, Zalewski A, Maier T, Peczuh MW, Ernst B. The price of flexibility - a case study on septanoses as pyranose mimetics. Chem Sci 2017; 9:646-654. [PMID: 29629131 PMCID: PMC5868388 DOI: 10.1039/c7sc04289b] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Accepted: 11/07/2017] [Indexed: 12/22/2022] Open
Abstract
Seven-membered ring mimetics of mannose were studied as ligands for the mannose-specific bacterial lectin FimH, which plays an essential role in the first step of urinary tract infections (UTI). A competitive binding assay and isothermal titration calorimetry (ITC) experiments indicated an approximately ten-fold lower affinity for the seven-membered ring mannose mimetic 2-O-n-heptyl-1,6-anhydro-d-glycero-d-galactitol (7) compared to n-heptyl α-d-mannopyranoside (2), resulting exclusively from a loss of conformational entropy. Investigations by solution NMR, X-ray crystallography, and molecular modeling revealed that 7 establishes a superimposable H-bond network compared to mannoside 2, but at the price of a high entropic penalty due to the loss of its pronounced conformational flexibility. These results underscore the importance of having access to the complete thermodynamic profile of a molecular interaction to "rescue" ligands from entropic penalties with an otherwise perfect fit to the protein binding site.
Collapse
Affiliation(s)
- Christoph P Sager
- University of Basel , Institute of Molecular Pharmacy , Pharmacenter of the University of Basel , Klingelbergstrasse 50 , 4056 , Basel , Switzerland .
| | - Brigitte Fiege
- University of Basel , Institute of Molecular Pharmacy , Pharmacenter of the University of Basel , Klingelbergstrasse 50 , 4056 , Basel , Switzerland .
| | - Pascal Zihlmann
- University of Basel , Institute of Molecular Pharmacy , Pharmacenter of the University of Basel , Klingelbergstrasse 50 , 4056 , Basel , Switzerland .
| | - Raghu Vannam
- Department of Chemistry , University of Connecticut , 55 N. Eagleville Road U3060, Storrs , CT , 06279 USA .
| | - Said Rabbani
- University of Basel , Institute of Molecular Pharmacy , Pharmacenter of the University of Basel , Klingelbergstrasse 50 , 4056 , Basel , Switzerland .
| | - Roman P Jakob
- University of Basel , Biozentrum: Focal Area Structural Biology , Klingelbergstrasse 70 , 4056 Basel , Switzerland
| | - Roland C Preston
- University of Basel , Institute of Molecular Pharmacy , Pharmacenter of the University of Basel , Klingelbergstrasse 50 , 4056 , Basel , Switzerland .
| | - Adam Zalewski
- University of Basel , Institute of Molecular Pharmacy , Pharmacenter of the University of Basel , Klingelbergstrasse 50 , 4056 , Basel , Switzerland .
| | - Timm Maier
- University of Basel , Biozentrum: Focal Area Structural Biology , Klingelbergstrasse 70 , 4056 Basel , Switzerland
| | - Mark W Peczuh
- Department of Chemistry , University of Connecticut , 55 N. Eagleville Road U3060, Storrs , CT , 06279 USA .
| | - Beat Ernst
- University of Basel , Institute of Molecular Pharmacy , Pharmacenter of the University of Basel , Klingelbergstrasse 50 , 4056 , Basel , Switzerland .
| |
Collapse
|
36
|
Frei P, Pang L, Silbermann M, Eriş D, Mühlethaler T, Schwardt O, Ernst B. Target-directed Dynamic Combinatorial Chemistry: A Study on Potentials and Pitfalls as Exemplified on a Bacterial Target. Chemistry 2017; 23:11570-11577. [PMID: 28654733 DOI: 10.1002/chem.201701601] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Indexed: 12/28/2022]
Abstract
Target-directed dynamic combinatorial chemistry (DCC) is an emerging technique for the efficient identification of inhibitors of pharmacologically relevant targets. In this contribution, we present an application for a bacterial target, the lectin FimH, a crucial virulence factor of uropathogenic E. coli being the main cause of urinary tract infections. A small dynamic library of acylhydrazones was formed from aldehydes and hydrazides and equilibrated at neutral pH in presence of aniline as nucleophilic catalyst. The major success factors turned out to be an accordingly adjusted ratio of scaffolds and fragments, an adequate sample preparation prior to HPLC analysis, and the data processing. Only then did the ranking of the dynamic library constituents correlate well with affinity data. Furthermore, as a support of DCC applications especially to larger libraries, a new protocol for improved hit identification was established.
Collapse
Affiliation(s)
- Priska Frei
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Lijuan Pang
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Marleen Silbermann
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Deniz Eriş
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Tobias Mühlethaler
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Oliver Schwardt
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| |
Collapse
|
37
|
Aeschbacher T, Zierke M, Smieško M, Collot M, Mallet JM, Ernst B, Allain FHT, Schubert M. A Secondary Structural Element in a Wide Range of Fucosylated Glycoepitopes. Chemistry 2017; 23:11598-11610. [PMID: 28654715 DOI: 10.1002/chem.201701866] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2017] [Indexed: 01/12/2023]
Abstract
The increasing understanding of the essential role of carbohydrates in development, and in a wide range of diseases fuels a rapidly growing interest in the basic principles governing carbohydrate-protein interactions. A still heavily debated issue regarding the recognition process is the degree of flexibility or rigidity of oligosaccharides. Combining NMR structure determination based on extensive experimental data with DFT and database searches, we have identified a set of trisaccharide motifs with a similar conformation that is characterized by a non-conventional C-H⋅⋅⋅O hydrogen bond. These motifs are present in numerous classes of oligosaccharides, found in everything from bacteria to mammals, including Lewis blood group antigens but also unusual motifs from amphibians and marine invertebrates. The set of trisaccharide motifs can be summarized with the consensus motifs X-β1,4-[Fucα1,3]-Y and X-β1,3-[Fucα1,4]-Y-a secondary structure we name [3,4]F-branch. The wide spectrum of possible modifications of this scaffold points toward a large variety of glycoepitopes, which nature generated using the same underlying architecture.
Collapse
Affiliation(s)
- Thomas Aeschbacher
- Institute of Molecular Biology and Biophysics, ETH Zürich, 8093, Zurich, Switzerland
| | - Mirko Zierke
- Institute of Molecular Pharmacy, University of Basel, Klingelbergstr. 50, 4056, Basel, Switzerland.,Department of Chemistry, University of British Columbia, V6T 1Z1, Vancouver, British Columbia, Canada
| | - Martin Smieško
- Institute of Molecular Pharmacy, University of Basel, Klingelbergstr. 50, 4056, Basel, Switzerland
| | - Mayeul Collot
- Laboratoire des Biomolécules, Département de Chimie, École normale supérieure, PSL Research University, Sorbonne Universités, UPMC Univ. Paris 06, CNRS, 24 rue Lhomond, 75005, Paris, France.,UMR 7213 CNRS, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, 74 route du Rhin, CS 60024, 67401, Illkirch, France
| | - Jean-Maurice Mallet
- Laboratoire des Biomolécules, Département de Chimie, École normale supérieure, PSL Research University, Sorbonne Universités, UPMC Univ. Paris 06, CNRS, 24 rue Lhomond, 75005, Paris, France
| | - Beat Ernst
- Institute of Molecular Pharmacy, University of Basel, Klingelbergstr. 50, 4056, Basel, Switzerland
| | - Frédéric H-T Allain
- Institute of Molecular Biology and Biophysics, ETH Zürich, 8093, Zurich, Switzerland
| | - Mario Schubert
- Institute of Molecular Biology and Biophysics, ETH Zürich, 8093, Zurich, Switzerland.,Institute of Molecular Biology, University of Salzburg, Billrothstr. 11, 5020, Salzburg, Austria
| |
Collapse
|
38
|
Mayer K, Eris D, Schwardt O, Sager CP, Rabbani S, Kleeb S, Ernst B. Urinary Tract Infection: Which Conformation of the Bacterial Lectin FimH Is Therapeutically Relevant? J Med Chem 2017; 60:5646-5662. [PMID: 28471659 DOI: 10.1021/acs.jmedchem.7b00342] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Frequent antibiotic treatment of urinary tract infections has resulted in the emergence of antimicrobial resistance, necessitating alternative treatment options. One such approach centers around FimH antagonists that block the bacterial adhesin FimH, which would otherwise mediate binding of uropathogenic Escherichia coli to the host urothelium to trigger the infection. Although the FimH lectin can adopt three distinct conformations, the evaluation of FimH antagonists has mainly been performed with a truncated construct of FimH locked in one particular conformation. For a successful therapeutic application, however, FimH antagonists should be efficacious against all physiologically relevant conformations. Therefore, FimH constructs with the capacity to adopt various conformations were applied. By examining the binding properties of a series of FimH antagonists in terms of binding affinity and thermodynamics, we demonstrate that depending on the FimH construct, affinities may be overestimated by a constant factor of 2 orders of magnitude. In addition, we report several antagonists with excellent affinities for all FimH conformations.
Collapse
Affiliation(s)
- Katharina Mayer
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Deniz Eris
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Oliver Schwardt
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Christoph P Sager
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Said Rabbani
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Simon Kleeb
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, Department of Pharmaceutical Sciences, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| |
Collapse
|
39
|
Navarra G, Zihlmann P, Jakob RP, Stangier K, Preston RC, Rabbani S, Smiesko M, Wagner B, Maier T, Ernst B. Cover Picture: Carbohydrate-Lectin Interactions: An Unexpected Contribution to Affinity (ChemBioChem 6/2017). Chembiochem 2017. [DOI: 10.1002/cbic.201700085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Giulio Navarra
- Institute of Molecular Pharmacy; Pharmacenter; University of Basel; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Pascal Zihlmann
- Institute of Molecular Pharmacy; Pharmacenter; University of Basel; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Roman P. Jakob
- Biozentrum; Focal Area Structural Biology; University of Basel; Klingelbergstrasse 70 4056 Basel Switzerland
| | - Katja Stangier
- Institute of Molecular Pharmacy; Pharmacenter; University of Basel; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Roland C. Preston
- Institute of Molecular Pharmacy; Pharmacenter; University of Basel; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Said Rabbani
- Institute of Molecular Pharmacy; Pharmacenter; University of Basel; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Martin Smiesko
- Institute of Molecular Pharmacy; Pharmacenter; University of Basel; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Bea Wagner
- Institute of Molecular Pharmacy; Pharmacenter; University of Basel; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Timm Maier
- Biozentrum; Focal Area Structural Biology; University of Basel; Klingelbergstrasse 70 4056 Basel Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy; Pharmacenter; University of Basel; Klingelbergstrasse 50 4056 Basel Switzerland
| |
Collapse
|
40
|
Navarra G, Zihlmann P, Jakob RP, Stangier K, Preston RC, Rabbani S, Smiesko M, Wagner B, Maier T, Ernst B. Carbohydrate-Lectin Interactions: An Unexpected Contribution to Affinity. Chembiochem 2017; 18:539-544. [PMID: 28076665 DOI: 10.1002/cbic.201600615] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Indexed: 11/07/2022]
Abstract
Uropathogenic E. coli exploit PapG-II adhesin for infecting host cells of the kidney; the expression of PapG-II at the tip of bacterial pili correlates with the onset of pyelonephritis in humans, a potentially life-threatening condition. It was envisaged that blocking PapG-II (and thus bacterial adhesion) would provide a viable therapeutic alternative to conventional antibiotic treatment. In our search for potent PapG-II antagonists, we observed an increase in affinity when tetrasaccharide 1, the natural ligand of PapG-II in human kidneys, was elongated to hexasaccharide 2, even though the additional Siaα(2-3)Gal extension is not in direct contact with the lectin. ITC studies suggest that the increased affinity results from partial desolvation of nonbinding regions of the hexasaccharide; this is ultimately responsible for perturbation of the outer hydration layers. Our results are in agreement with previous observations and suggest a general mechanism for modulating carbohydrate-protein interactions based on nonbinding regions of the ligand.
Collapse
Affiliation(s)
- Giulio Navarra
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Pascal Zihlmann
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Roman P Jakob
- Biozentrum, Focal Area Structural Biology, University of Basel, Klingelbergstrasse 70, 4056, Basel, Switzerland
| | - Katja Stangier
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Roland C Preston
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Said Rabbani
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Martin Smiesko
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Bea Wagner
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Timm Maier
- Biozentrum, Focal Area Structural Biology, University of Basel, Klingelbergstrasse 70, 4056, Basel, Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland
| |
Collapse
|
41
|
Rabbani S, Krammer EM, Roos G, Zalewski A, Preston R, Eid S, Zihlmann P, Prévost M, Lensink MF, Thompson A, Ernst B, Bouckaert J. Mutation of Tyr137 of the universal Escherichia coli fimbrial adhesin FimH relaxes the tyrosine gate prior to mannose binding. IUCrJ 2017; 4:7-23. [PMID: 28250938 PMCID: PMC5331462 DOI: 10.1107/s2052252516016675] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 10/18/2016] [Indexed: 05/08/2023]
Abstract
The most prevalent diseases manifested by Escherichia coli are acute and recurrent bladder infections and chronic inflammatory bowel diseases such as Crohn's disease. E. coli clinical isolates express the FimH adhesin, which consists of a mannose-specific lectin domain connected via a pilin domain to the tip of type 1 pili. Although the isolated FimH lectin domain has affinities in the nanomolar range for all high-mannosidic glycans, differentiation between these glycans is based on their capacity to form predominantly hydrophobic interactions within the tyrosine gate at the entrance to the binding pocket. In this study, novel crystal structures of tyrosine-gate mutants of FimH, ligand-free or in complex with heptyl α-d-O-mannopyranoside or 4-biphenyl α-d-O-mannopyranoside, are combined with quantum-mechanical calculations and molecular-dynamics simulations. In the Y48A FimH crystal structure, a large increase in the dynamics of the alkyl chain of heptyl α-d-O-mannopyranoside attempts to compensate for the absence of the aromatic ring; however, the highly energetic and stringent mannose-binding pocket of wild-type FimH is largely maintained. The Y137A mutation, on the other hand, is the most detrimental to FimH affinity and specificity: (i) in the absence of ligand the FimH C-terminal residue Thr158 intrudes into the mannose-binding pocket and (ii) ethylenediaminetetraacetic acid interacts strongly with Glu50, Thr53 and Asn136, in spite of multiple dialysis and purification steps. Upon mutation, pre-ligand-binding relaxation of the backbone dihedral angles at position 137 in the tyrosine gate and their coupling to Tyr48 via the interiorly located Ile52 form the basis of the loss of affinity of the FimH adhesin in the Y137A mutant.
Collapse
Affiliation(s)
- Said Rabbani
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Eva-Maria Krammer
- University of Lille, CNRS UMR8576 UGSF (Unité de Glycobiologie Structurale et Fonctionnelle), 59000 Lille, France
- Structure et Fonction des Membranes Biologiques, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - Goedele Roos
- University of Lille, CNRS UMR8576 UGSF (Unité de Glycobiologie Structurale et Fonctionnelle), 59000 Lille, France
- Structure et Fonction des Membranes Biologiques, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - Adam Zalewski
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Roland Preston
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Sameh Eid
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Pascal Zihlmann
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Martine Prévost
- Structure et Fonction des Membranes Biologiques, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - Marc F. Lensink
- University of Lille, CNRS UMR8576 UGSF (Unité de Glycobiologie Structurale et Fonctionnelle), 59000 Lille, France
| | - Andrew Thompson
- Synchrotron SOLEIL, l’Orme de Merisiers, Saint-Aubin BP48, Gif-sur-Yvette CEDEX, France
| | - Beat Ernst
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50-70, CH-4056 Basel, Switzerland
| | - Julie Bouckaert
- University of Lille, CNRS UMR8576 UGSF (Unité de Glycobiologie Structurale et Fonctionnelle), 59000 Lille, France
| |
Collapse
|
42
|
Abstract
The bacterial lectin FimH is a promising therapeutic target for the nonantibiotic prevention and treatment of urinary tract infections. In this communication, an ester prodrug approach is described to achieve oral bioavailability for FimH antagonists. By introducing short-chain acyl promoieties at the C-6 position of a biphenyl α-d-mannopyranoside, prodrugs with an excellent absorption potential were obtained. The human carboxylesterase 2 was identified as a main enzyme mediating rapid bioconversion to the active principle. Despite their propensity to hydrolysis within the enterocytes during absorption, these ester prodrugs present a considerable progress in the development of orally available FimH antagonists.
Collapse
Affiliation(s)
- Wojciech Schönemann
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| | - Simon Kleeb
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| | - Philipp Dätwyler
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| | - Oliver Schwardt
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland
| |
Collapse
|
43
|
Leinung M, Zaretsky Y, Ernst B, Vaerst B, Stöver T, Hey C. [Vibrant Soundbridge®: An Alternative Hearing System for Preschool Children with Aural Atresia]. Laryngorhinootologie 2016; 95:627-33. [PMID: 27626815 DOI: 10.1055/s-0042-100906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND The audiological treatment of children with aural atresia makes high demands on physicians and acousticians. Conventional hearing systems are often not tolerated by children and therefore do not meet the needs of the early and efficient therapy of hearing disorders. Aim of the present study was the evaluation of the audiological functional gain in children with uni- and bilateral aural atresia provided with the middle ear implant Vibrant Soundbridge(®) (VSB(®)) below the age of 6 years as well as the analysis of parents' satisfaction assessed with questionnaires. MATERIAL AND METHODS The VSB(®) was implanted in 16 children, 13 with unilateral and 3 with bilateral aural atresia, with the mean age of 2;11±1;6 years. 3 months after the first fitting of the audio processor, pure-tone audiometry via free field testing with and without the hearing system was performed. Furthermore, parents completed a standardized questionnaire to evaluate their satisfaction with the VSB(®) treatment quality. The questionnaire included items on the acceptance by children, handling, listening effort, behavior, satisfaction, quality of life, aesthetics, and the length of daily use. RESULTS The use of the VSB(®) resulted in a significantly improved hearing level: 20 dB on average (Z=- 3.06; p=0.002; n=12). The analysis of parents' questionnaire demonstrated high or very high satisfaction with VSB(®) in all subjects. Primarily, the length of daily use of the VSB(®) was significantly higher than that of the hearing system used before with 10.0±2.1 vs. 2.7±2.2 h per day (Z=- 3.06; p=0.002; n=14). CONCLUSION The VSB(®) presented a good alternative for audiological treatment of uni- and bilateral aural atresia at toddler and pre-school age.
Collapse
Affiliation(s)
- M Leinung
- Klinik für Hals-, Nasen-, Ohrenheilkunde, Klinikum der J.W. Goethe-Universität Frankfurt am Main, Frankfurt am Main
| | - Y Zaretsky
- Abteilung für Phoniatrie und Pädaudiologie, Universitätsklinikum Giessen und Marburg, Marburg
| | - B Ernst
- Hals-, Nasen-, Ohrenklinik und Poliklinik, Johannes Gutenberg Universitat Mainz, Mainz
| | - B Vaerst
- Department for Ear Nose Throat Medicine, University of Frankfurt/Main, Frankfurt
| | - T Stöver
- HNO, Universitätsklinikum Frankfurt, Frankfurt
| | - C Hey
- Abteilung für Phoniatrie und Pädaudiologie, Universitätsklinikum Gießen-Marburg, Standort Marburg, Marburg, Hessen
| |
Collapse
|
44
|
Eris D, Preston RC, Scharenberg M, Hulliger F, Abgottspon D, Pang L, Jiang X, Schwardt O, Ernst B. Back Cover: The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target? (ChemBioChem 11/2016). Chembiochem 2016. [DOI: 10.1002/cbic.201600279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Deniz Eris
- Department of Pharmaceutical Sciences; Institute of Molecular Pharmacy; Pharmacenter; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Roland C. Preston
- Department of Pharmaceutical Sciences; Institute of Molecular Pharmacy; Pharmacenter; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Meike Scharenberg
- Department of Pharmaceutical Sciences; Institute of Molecular Pharmacy; Pharmacenter; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Fabian Hulliger
- Department of Pharmaceutical Sciences; Institute of Molecular Pharmacy; Pharmacenter; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Daniela Abgottspon
- Department of Pharmaceutical Sciences; Institute of Molecular Pharmacy; Pharmacenter; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Lijuan Pang
- Department of Pharmaceutical Sciences; Institute of Molecular Pharmacy; Pharmacenter; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Xiaohua Jiang
- Department of Pharmaceutical Sciences; Institute of Molecular Pharmacy; Pharmacenter; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Oliver Schwardt
- Department of Pharmaceutical Sciences; Institute of Molecular Pharmacy; Pharmacenter; Klingelbergstrasse 50 4056 Basel Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences; Institute of Molecular Pharmacy; Pharmacenter; Klingelbergstrasse 50 4056 Basel Switzerland
| |
Collapse
|
45
|
Wipf M, Stoop RL, Navarra G, Rabbani S, Ernst B, Bedner K, Schönenberger C, Calame M. Label-Free FimH Protein Interaction Analysis Using Silicon Nanoribbon BioFETs. ACS Sens 2016. [DOI: 10.1021/acssensors.6b00089] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | | | | | | | | | - Kristine Bedner
- Laboratory
for Micro- and Nanotechnology, Paul Scherrer Institut, 5232 Villigen, Switzerland
| | | | | |
Collapse
|
46
|
Eris D, Preston RC, Scharenberg M, Hulliger F, Abgottspon D, Pang L, Jiang X, Schwardt O, Ernst B. The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target? Chembiochem 2016; 17:1012-20. [PMID: 26991759 DOI: 10.1002/cbic.201600066] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Indexed: 12/21/2022]
Abstract
FimH is a bacterial lectin found at the tips of type 1 pili of uropathogenic Escherichia coli (UPEC). It mediates shear-enhanced adhesion to mannosylated surfaces. Binding of UPEC to urothelial cells initiates the infection cycle leading to urinary tract infections (UTIs). Antiadhesive glycomimetics based on α-d-mannopyranose offer an attractive alternative to the conventional antibiotic treatment because they do not induce a selection pressure and are therefore expected to have a reduced resistance potential. Genetic variation of the fimH gene in clinically isolated UPEC has been associated with distinct mannose binding phenotypes. For this reason, we investigated the mannose binding characteristics of four FimH variants with mannose-based ligands under static and hydrodynamic conditions. The selected FimH variants showed individually different binding behavior under both sets of conditions as a result of the conformational variability of FimH. Clinically relevant FimH variants typically exist in a dynamic conformational equilibrium. Additionally, we evaluated inhibitory potencies of four FimH antagonists representing different structural classes. Inhibitory potencies of three of the tested antagonists were dependent on the binding phenotype and hence on the conformational equilibrium of the FimH variant. However, the squarate derivative was the notable exception and inhibited FimH variants irrespective of their binding phenotype. Information on antagonist affinities towards various FimH variants has remained largely unconsidered despite being essential for successful antiadhesion therapy.
Collapse
Affiliation(s)
- Deniz Eris
- Department of Pharmaceutical Sciences, Institute of Molecular Pharmacy, Pharmacenter, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Roland C Preston
- Department of Pharmaceutical Sciences, Institute of Molecular Pharmacy, Pharmacenter, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Meike Scharenberg
- Department of Pharmaceutical Sciences, Institute of Molecular Pharmacy, Pharmacenter, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Fabian Hulliger
- Department of Pharmaceutical Sciences, Institute of Molecular Pharmacy, Pharmacenter, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Daniela Abgottspon
- Department of Pharmaceutical Sciences, Institute of Molecular Pharmacy, Pharmacenter, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Lijuan Pang
- Department of Pharmaceutical Sciences, Institute of Molecular Pharmacy, Pharmacenter, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Xiaohua Jiang
- Department of Pharmaceutical Sciences, Institute of Molecular Pharmacy, Pharmacenter, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Oliver Schwardt
- Department of Pharmaceutical Sciences, Institute of Molecular Pharmacy, Pharmacenter, Klingelbergstrasse 50, 4056, Basel, Switzerland
| | - Beat Ernst
- Department of Pharmaceutical Sciences, Institute of Molecular Pharmacy, Pharmacenter, Klingelbergstrasse 50, 4056, Basel, Switzerland.
| |
Collapse
|
47
|
Kleeb S, Jiang X, Frei P, Sigl A, Bezençon J, Bamberger K, Schwardt O, Ernst B. FimH Antagonists: Phosphate Prodrugs Improve Oral Bioavailability. J Med Chem 2016; 59:3163-82. [PMID: 26959338 DOI: 10.1021/acs.jmedchem.5b01923] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The widespread occurrence of urinary tract infections has resulted in frequent antibiotic treatment, contributing to the emergence of antimicrobial resistance. Alternative approaches are therefore required. In the initial step of colonization, FimH, a lectin located at the tip of bacterial type 1 pili, interacts with mannosylated glycoproteins on the urothelial mucosa. This initial pathogen/host interaction is efficiently antagonized by biaryl α-d-mannopyranosides. However, their poor physicochemical properties, primarily resulting from low aqueous solubility, limit their suitability as oral treatment option. Herein, we report the syntheses and pharmacokinetic evaluation of phosphate prodrugs, which show an improved aqueous solubility of up to 140-fold. In a Caco-2 cell model, supersaturated solutions of the active principle were generated through hydrolysis of the phosphate esters by brush border-associated enzymes, leading to a high concentration gradient across the cell monolayer. As a result, the in vivo application of phosphate prodrugs led to a substantially increased Cmax and prolonged availability of FimH antagonists in urine.
Collapse
Affiliation(s)
- Simon Kleeb
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Xiaohua Jiang
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Priska Frei
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Anja Sigl
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Jacqueline Bezençon
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Karen Bamberger
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Oliver Schwardt
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, Pharmacenter, University of Basel , Klingelbergstrasse 50, 4056 Basel, Switzerland
| |
Collapse
|
48
|
Sauer MM, Jakob RP, Eras J, Baday S, Eriş D, Navarra G, Bernèche S, Ernst B, Maier T, Glockshuber R. Catch-bond mechanism of the bacterial adhesin FimH. Nat Commun 2016; 7:10738. [PMID: 26948702 PMCID: PMC4786642 DOI: 10.1038/ncomms10738] [Citation(s) in RCA: 126] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Accepted: 01/13/2016] [Indexed: 01/12/2023] Open
Abstract
Ligand–receptor interactions that are reinforced by mechanical stress, so-called catch-bonds, play a major role in cell–cell adhesion. They critically contribute to widespread urinary tract infections by pathogenic Escherichia coli strains. These pathogens attach to host epithelia via the adhesin FimH, a two-domain protein at the tip of type I pili recognizing terminal mannoses on epithelial glycoproteins. Here we establish peptide-complemented FimH as a model system for fimbrial FimH function. We reveal a three-state mechanism of FimH catch-bond formation based on crystal structures of all states, kinetic analysis of ligand interaction and molecular dynamics simulations. In the absence of tensile force, the FimH pilin domain allosterically accelerates spontaneous ligand dissociation from the FimH lectin domain by 100,000-fold, resulting in weak affinity. Separation of the FimH domains under stress abolishes allosteric interplay and increases the affinity of the lectin domain. Cell tracking demonstrates that rapid ligand dissociation from FimH supports motility of piliated E. coli on mannosylated surfaces in the absence of shear force. Catch bonds have a role in bacterial adhesion and infection by uropathogenic E. coli. Here, the authors report crystal structures, molecular dynamics simulations, ligand binding analysis and cell tracking to characterise the catch bond interaction between the adhesin FimH and carbohydrate receptors.
Collapse
Affiliation(s)
- Maximilian M Sauer
- Institute of Molecular Biology and Biophysics, Department of Biology, ETH, Zurich, Otto-Stern-Weg 5, 8093 Zurich, Switzerland
| | - Roman P Jakob
- Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
| | - Jonathan Eras
- Institute of Molecular Biology and Biophysics, Department of Biology, ETH, Zurich, Otto-Stern-Weg 5, 8093 Zurich, Switzerland
| | - Sefer Baday
- Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland.,SIB Swiss Institute of Bioinformatics, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
| | - Deniz Eriş
- Institute of Molecular Pharmacy, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Giulio Navarra
- Institute of Molecular Pharmacy, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Simon Bernèche
- Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland.,SIB Swiss Institute of Bioinformatics, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
| | - Beat Ernst
- Institute of Molecular Pharmacy, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Timm Maier
- Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
| | - Rudi Glockshuber
- Institute of Molecular Biology and Biophysics, Department of Biology, ETH, Zurich, Otto-Stern-Weg 5, 8093 Zurich, Switzerland
| |
Collapse
|
49
|
Teppner M, Boess F, Ernst B, Pahler A. Biomarkers of Flutamide-Bioactivation and Oxidative Stress In Vitro and In Vivo. Drug Metab Dispos 2016; 44:560-9. [DOI: 10.1124/dmd.115.066522] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Accepted: 01/06/2016] [Indexed: 11/22/2022] Open
|
50
|
Teppner M, Böss F, Ernst B, Pähler A. Application of lipid peroxidation products as biomarkers for flutamide-induced oxidative stress in vitro. Toxicol Lett 2015; 238:53-9. [DOI: 10.1016/j.toxlet.2015.08.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2014] [Revised: 07/24/2015] [Accepted: 08/04/2015] [Indexed: 12/12/2022]
|